US20170143959A1 - Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism - Google Patents

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism Download PDF

Info

Publication number
US20170143959A1
US20170143959A1 US15/423,791 US201715423791A US2017143959A1 US 20170143959 A1 US20170143959 A1 US 20170143959A1 US 201715423791 A US201715423791 A US 201715423791A US 2017143959 A1 US2017143959 A1 US 2017143959A1
Authority
US
United States
Prior art keywords
neurostimulator
disorder
feed
stimulation lead
lead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/423,791
Inventor
Carl Lance Boling
Benjamin David Pless
Ryan Powell
Anthony V. Caparso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autonomic Technologies Inc
Original Assignee
Autonomic Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autonomic Technologies Inc filed Critical Autonomic Technologies Inc
Priority to US15/423,791 priority Critical patent/US20170143959A1/en
Publication of US20170143959A1 publication Critical patent/US20170143959A1/en
Assigned to AUTONOMIC TECHNOLOGIES, INC. reassignment AUTONOMIC TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOLING, CARL LANCE, CAPARSO, ANTHONY V., PLESS, BENJAMIN DAVID, POWELL, RYAN
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • A61N1/0546Nasal electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • A61N1/0558Anchoring or fixation means therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36064Epilepsy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36067Movement disorders, e.g. tremor or Parkinson disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain
    • A61N1/36075Headache or migraine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36078Inducing or controlling sleep or relaxation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37211Means for communicating with stimulators
    • A61N1/37217Means for communicating with stimulators characterised by the communication link, e.g. acoustic or tactile
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/375Constructional arrangements, e.g. casings
    • A61N1/3752Details of casing-lead connections
    • A61N1/3754Feedthroughs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/378Electrical supply
    • A61N1/3787Electrical supply from an external energy source
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/375Constructional arrangements, e.g. casings
    • A61N1/37518Anchoring of the implants, e.g. fixation

Definitions

  • the invention relates generally to a stimulating apparatus used to deliver electrical stimulation to a peripheral, central or autonomic neural structure. More specifically, the current invention relates to a neurostimulator apparatus designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) to treat primary headaches, such as migraines, cluster headaches and/or many other neurological disorders, such as atypical facial pain and/or trigeminal neuralgias.
  • SPG sphenopalatine ganglion
  • headaches are one of the most debilitating ailments that afflict millions of individuals worldwide. The specific pathophysiology of headaches is unknown. Known sources of headache pain consist of trauma, vascular, autoimmune, degenerative, infectious, drug and medication-induced, inflammatory, neoplastic, metabolic-endocrine, iatrogenic, musculoskeletal and myofacial causes. Also, even though the possible underlying cause of the headache pain is identified and treated, the headache pain may persist.
  • SPG sphenopalatine ganglion
  • the SPG is a large extra cranial parasympathetic ganglion. It consists of parasympathetic neurons that innervate (in part) the middle cerebral and anterior cerebral blood vessels, the facial blood vessels, and the lacrimal glands.
  • a ganglion is a mass of nervous tissue found in some peripheral and autonomic nerves. Ganglia are located on the roots of the spinal nerves and on the roots of the trigeminal nerve. Ganglia are also located on the facial, glossopharyngeal, vagus and vestibulochoclear nerves.
  • the SPG is a complex neural ganglion with multiple connections, including autonomic, sensory and motor.
  • the maxillary branch of the trigeminal nerve and the nerve of the pterygoid canal, also known as the vidian nerve, which is formed by the greater and deep petrosal nerves send neural projections to the SPG.
  • the fine branches from the maxillary nerve (pterygopalatine nerves) form the sensory component of the SPG, and these fibers pass through the SPG and do not synapse.
  • the greater petrosal nerve carries the preganglionic parasympathetic axons from the superior salivary nucleus, which is located in the Pons, to the SPG. These fibers synapse onto the postganglionic neurons within the SPG.
  • the deep petrosal nerve connects the superior cervical sympathetic ganglion to the SPG and carries postganglionic sympathetic axons that again pass through the SPG without any synapses.
  • the sphenopalatine ganglion also called the pterygopalatine ganglion, is located within the pterygopalatine fossa.
  • the pterygopalatine fossa PPF
  • PPF pterygopalatine fossa
  • PMF pterygomaxillary fissure
  • Treatment of the SPG is mostly performed in attempted treatments of severe headaches, such as cluster headaches or chronic migraines.
  • Various clinical approaches have been used for over 100 years to modulate the function of the SPG to treat headaches. These procedures vary from least invasive (e.g., transnasal anesthetic blocks) to much more invasive (e.g., surgical ganglionectomy) as well as procedures such as surgical anesthetic injections, ablations, gamma knife and cryogenic surgery. Most of these procedures have very good short term efficacy outcomes (days to months), however these results are usually temporary and the headache pain returns.
  • a chronically implanted neurostimulator apparatus designed to deliver electrical stimulation to the SPG may provide much better long term efficacy in these patients. This application details the design of a neurostimulator for this purpose.
  • an implantable medical device configured for delivery of electrical stimulation to the Sphenopalatine Ganglion (SPG)
  • SPG Sphenopalatine Ganglion
  • the device further comprises a fixation apparatus integral to the electronics enclosure.
  • the fixation apparatus can comprise at least one preformed hole configured to accept a bone screw.
  • the fixation apparatus is malleable and configured to be formed around the zygomaticomaxillary buttress.
  • the electronics enclosure comprises an ASIC, an inductive coil, and a diode array.
  • the implantable medical device is sized and configured for implantation into the pterygopalatine fossa. In other embodiments, the implantable medical device is sized and configured for implantation on the posterior maxilla.
  • the device further comprises a stimulation lead coupled to the electronics enclosure.
  • the stimulation lead can be constructed to an angle off an axis of the electronics enclosure. In some embodiments, the angle is approximately 0 to 60 degrees. In other embodiments, the angle is approximately 30 degrees.
  • the implantable medical device is configured to lay fiat against the posterior maxilla, and the stimulation lead is angled so as to maintain contact with the posterior maxilla as it extends to the pterygopalatine fossa.
  • the stimulation lead is sized and configured to pass through a lateral opening of the pterygopalatine fossa. In some embodiments, a diameter of the stimulation lead is approximately 2-12 mm.
  • the device can further comprise at least one electrode disposed on the stimulation lead.
  • the device can further comprise at least one electrode wire coupling the at least one electrode to the electronics enclosure.
  • the device further comprises a platinum/iridium tubing configured to connect the at least one electrode wire to the monolithic feed-through.
  • the platinum/iridium tubing comprises at least one witness hole.
  • the device comprises a thin-film flex circuit configured to connect the at least one electrode wire to the monolithic feed-through.
  • a protrusion feature is disposed on the monolithic feed-through.
  • Some embodiments of the device further comprise an inductive coil configured to receive power and communication from an external controller at a depth of approximately 1-3 cm.
  • the electronics enclosure comprises an ASIC printed on the electronics enclosure.
  • Another embodiment further comprises at least one annular ring coupled to the electronics enclosure and configured to receive exposed ends of the monolithic feed-through.
  • the device further comprises a stiffening mechanism configured to increase the linear stiffness of the stimulation lead.
  • the stiffening mechanism comprises a malleable wire.
  • the stiffening mechanism comprises a coiled wire.
  • the stiffening mechanism comprises a tapered supporting wire.
  • An implantable stimulator configured for delivery of electrical stimulation to a nerve
  • the stimulator comprises an attachment plate coupled to the housing, the attachment plate configured to accept a bone screw for attachment to bone.
  • FIG. 1 is a lateral view the neurostimulator in communication with the anatomy
  • FIG. 2 is an isometric view of the neurostimulator
  • FIGS. 3 a -3 b are top and side section views of the neurostimulator
  • FIG. 4 is a transparent view illustrating the electrode wire interconnects
  • FIG. 5 is a transparent view illustrating an electrode flex circuit interconnect
  • FIG. 6 is an isometric view of a feed-through interconnect embodiment
  • FIG. 7 is an exploded view of the neurostimulator's electronics enclosure
  • FIG. 8 is an exploded view of an electronics enclosure embodiment
  • FIG. 9 is an isometric view of the electronics enclosure embodiment
  • FIG. 10 is a top down view of the neurostimulator's electronics and enclosure
  • FIG. 11 is an isometric view of a feed-through interconnect embodiment
  • FIG. 12 illustrates embodiments of the lead cross-sections
  • FIG. 13 illustrates axial cross-sectional insets of lead embodiments
  • FIG. 14 is an isometric view of an embodiment of a bendable lead
  • FIG. 15 is an isometric view of an embodiment of a bendable lead
  • FIG. 16 is an isometric view of an embodiment of a bendable lead.
  • a neurostirnulator 100 is shown within the intended anatomy for the treatment of primary headaches and other neurological disorders.
  • the neurostimulator of this embodiment comprises of a stimulator body 200 a , an integral stimulation lead 200 b , and an integral fixation apparatus 200 c .
  • the neurostimulator 100 can be implanted such that the stimulator body 200 b is positioned medial to the zygoma 205 on the posterior maxilla 206 within the buccal fat pad of the cheek, and the integral fixation apparatus 200 c is anchored to the zygomaticomaxillary buttress 203 , such as by using standard craniomaxillofacial bone screws, for example.
  • the integral stimulation lead 200 c can be placed within the pterygopalatine fossa 202 , or more specifically, in very close proximity to the sphenopalatine ganglion 204 .
  • FIG. 2 illustrates one embodiment of an implantable neurostirnulator 200 .
  • the neurostimulator 200 comprises of a stimulator body 200 a , an integral stimulation lead 200 b , which includes one or more stimulating electrodes 201 , and an integral fixation apparatus 200 c .
  • the neurostimulator 200 of this embodiment can be an inductively powered device having the necessary micro-electronics to store programmable stimulation parameters, deliver electrical stimulation per the programmed parameters and to allow bi-directional telemetry to enable communication with an external controller.
  • An external transmitter (not shown) provides powers to and communications with the implanted neurostimulator.
  • the neurostimulator's micro-electronics can be housed in the stimulator body 200 a , a hermetic enclosure that protects the micro-electronics from fluid ingress when implanted within the body.
  • the stimulator body can further include an electronics enclosure, a micro-electronics assembly, a monolithic feed-through assembly, and a lead interconnect assembly, and the stimulator body can be molded with a protective outer layer.
  • the dimensions of the stimulator body are 8 mm wide, 4 mm thick, and 14 mm long.
  • the neurostimulator is sized and configured to be implanted on the posterior maxilla, so the neurostimulator thickness is limited by the available free space between the posterior maxilla and the coronoid process of the mandible.
  • the thickness of the neurostimulator can range from 1 to 10 mm.
  • the width and length of the neurostimulator are also limited by the surrounding anatomy, but in some embodiments the width and length are such that the neurostimulator maintains physical contact with the posterior maxilla.
  • the neurostimulation width can range from 1-20 mm, and the length can range from 1-25 mm.
  • Electrical stimulation can be carried from the micro-electronics to one or more of the stimulating electrodes 201 through the stimulation lead 200 b .
  • the stimulation lead can be connected to the stimulator body through a series of feed-through assemblies.
  • the stimulator body 200 a and a portion of the stimulating lead 200 b are shown with a biocompatible outer layer 202 , created using a reaction injection molding (RIM) process, to protect the feed-through assemblies, provide strain relief to the stimulation lead and create an isodiametric neurostimulator.
  • RIM reaction injection molding
  • the outer protective layer does not contain any sharp corners or edges. This allows the neurostimulator to be implanted and explanted without grabbing or tearing of surrounding tissue.
  • the outer protective layer is created from biocompatible urethane and silicone co-polymer.
  • the protective layer can be up to 1 mm thick, however in some embodiments the protective layer can be 0.1 to 2 mm thick.
  • different encapsulations methods and materials may be used, including but not limited to, potting, injection molding, casting, conformal coating, or adhering a compliant, semi-compliant, or rigid silicone rubber, epoxy, thereto-set or thermoplastic polymers or combination of any of the described methods and materials around the electronic assembly, lead interconnect, and lead assembly.
  • the integral fixation apparatus 200 c can include a. biocompatible mini-plate with one or more preformed holes extending off the body of the neurostimulator.
  • the preformed holes can be designed to accept a standard bone screw.
  • the preformed holes can be approximately 1.9 mm in diameter and be sized to accept a standard bone screw with a diameter between 1.5-1.8 mm.
  • the preformed holes can also be designed with a ninety-degree chamfer that allows the head of the standard bone screw to recess into the mini-plate and reside flush with the outboard face of mini-plate.
  • the mini-plate is made from titanium (grade 2), which provides both good mechanical fatigue resistance and good flexibility.
  • the mini-plate can be made from other materials such as: commercially pure titanium such as grades 1,3, or 4 and alloys such as grade 5 or 23; stainless steels such as 304 or 316; other biocompatible metals; and biocompatible plastics such as PEEK, nylon, or polypropylene.
  • the one or more preformed holes are set in a linear configuration off the proximal end of the stimulator body to increase the flexibility of the mini-plate.
  • the mini-plate can be anchored to the thick dense bone of the zygomatic process of the maxilla, generally referred to the zygomaticomaxillary buttress.
  • the mini-plate When the stimulator body is positioned on the posterior maxilla, the mini-plate must be formed around the buttress without adversely moving or dislodging the stimulator body and the stimulation lead.
  • the mini-plate must be malleable so that it can be formed around the buttress as well as resistant to flex fatigue from repeat bending.
  • the center-to-center distance between each of the preformed holes can be 6 mm, and the width of the beam between each preformed hole can be 1.3 mm.
  • the mini-plate provides the proper amount of malleability and flex resistance needed to form the mini-plate around the buttress and to allow for long term reliability for the chronic implantable neurostimulator.
  • the second moment of area across the mini-plate is designed to be constant, which facilitates uniform bending and typically creates a larger more uniform arch. The larger arch that is formed from bending of the mini-plate helps to resist stress concentrations and promotes matching of the surface of the mini-plate to the underlying anatomical bone features.
  • the center-to-center distance between each of the preformed holes can be between 3-10 mm and the width of the beam between each preformed hole can be 0.5 to 3 mm.
  • the arrangement of the preformed holes on the mini-plate can be configured into a Y configuration (a single mini-plate extending off the stimulator body with two tails extending out like a Y), a T configuration (a single mini-plate formed into a T), an L configuration (a single mini-plate formed into an L) or an X configuration (a single mini-plate formed into a X, with one leg of the X attached to the stimulator body).
  • each of the mini-plates can contain one or more preformed holes and include the same features described above.
  • the neurostimulator can include one or more mini-plates projecting off the stimulator body, including but not limited to a mini-plate extending off the opposing end of the stimulator body from the stimulating lead, and one or more mini-plates extending off the two other adjacent sides of the neurostimulator.
  • FIG. 2 also illustrates the stimulating lead 200 b of neurostimulator 200 .
  • the stimulating lead comprises of one or more stimulation electrodes 201 and a corresponding number of connecting lead wires for each of the stimulating electrodes.
  • Each connecting lead wire connects to a feed-through on the stimulating body.
  • the connecting wires provide a conduit to deliver electrical stimulation pulses between the micro-electronics and the stimulating electrodes.
  • the stimulation lead projects from the distal face of the stimulator body constructed to an angle of 30 degrees off the stimulator axis.
  • the inboard planer side of the neurostimulator body is configured to lay flat against and in interment communication with the posterior maxilla, which also coincides with the stimulator surface from which the integral fixation apparatus 200 c extends.
  • the angle of the stimulating lead projecting off the stimulator body allows the lead to maintain contact with the posterior maxilla as it courses from the stimulator body to the pterygopalatine fossa and reduces any stress on the stimulating lead by reducing the lead curvature.
  • the degree of the angle between the stimulator body and stimulating lead can range from between approximately 0 to 60 degrees.
  • the stimulating lead may contain multiple compound angles with the neurostimulator, the angles may be on or off axis with the stimulator body.
  • the stimulating lead includes seven cylindrical stimulating electrodes 201 that can be configured to provide either cathodic or anodic stimulation.
  • the stimulating lead comprises at least 5 stimulating cathodic electrodes, or working electrodes.
  • the working electrodes are configured to be implanted in very close proximity to the SPG within the pterygopalatine fossa and to be used for delivering the stimulation pulses from the micro-electronics.
  • the two most proximal electrodes to the stimulator body 200 a can be electronically coupled to create a larger reference or return electrode. This reference electrode can be configured as an anode and positioned on the stimulating lead such that it is the farthest electrode from the SPG.
  • the length and spacing of the electrodes are configured to optimize stimulation of the SPG.
  • the average height and width of the SPG has been found to be 3.28 mm, range 2-6 mm and 1.76 mm, range 1-3 mm respectively.
  • the spacing distance between any two adjacent stimulation electrodes is no greater than 1.0 mm and each electrode is 1.5 mm in length.
  • the electrode length and the spacing assures that at least one electrode maintains communication with the SPG.
  • the electrode spacing can range from 0.3-4 mm, and the length of each electrode can range from 0.4 to 4 mm.
  • the stimulating lead and hence each electrode is 1 mm in diameter.
  • the diameter of the stimulating lead can be designed such that the lead passes through the lateral opening the pterygopalatine fossa, called the pterygopalatine fissure, which has been reported to be between 2-12 mm wide. In other embodiment, the diameter of the lead can range from 0.5 to 3 mm.
  • Each stimulation electrode has a thickness of 0.1 mm; a minimum thickness of 0.05 mm is needed prevent damage during manufacturing and implantation.
  • the stimulation electrodes can be made from 90/10 platinum/iridium alloy.
  • the stimulation electrodes can be made from other biocompatible metallic alloys, including but not limited to platinum, platinum alloys, palladium, palladium alloys, titanium, titanium alloys, various stainless steels, or any other conductive biocompatible metals and biocompatible non-metals such as but not limited to carbon.
  • FIG. 3 a is an elevated view and FIG. 3 b is a sectioned side view of neurostimulator 300 , and illustrates the integral design of the neurostimilator.
  • the neurostimulator 300 includes stimulator body 300 a , integral stimulating lead 300 b , which includes one or more stimulation electrodes 301 , and integral fixation apparatus 300 c .
  • FIG. 3 b shows a sectioned side view of the neurostimulator through the line A-A in FIG. 3 a .
  • the sectioned side view shows the hermetic electronics enclosure within the stimulator body 300 a , integral stimulation lead 300 b , electrode wire interconnect assembly 305 and the electrode connection wires 303 . Also shown in FIG.
  • 3 b is the protective (insulation) outer layer 304 , which encapsulates the stimulator body and the proximal portion of the stimulation lead.
  • the protective layer also covers the proximal portion of the stimulation lead to provide additional strain relief at the junction between the lead and the stimulator body.
  • This layer is formed by reaction injection molding (RIM) with a biocompatible urethane and silicone co-polymer.
  • RIM reaction injection molding
  • Other encapsulations methods and materials may include potting, injection molding, casting, conformal coating, or adhering a compliant, semi-compliant, or rigid silicone rubber, epoxy, thermo set or thermoplastic polymers or combination of any of the described methods and materials around the electronic assembly, lead interconnect, and lead assembly.
  • FIG. 4 shows an enlarged detail view of the encapsulated hermetic electronics enclosure 411 , feed through assembly and interconnect assembly.
  • the feed-through wires 410 projecting from the upper surface of the hermetic electronic enclosure 411 can be bonded to the enclosure.
  • the feed-through wires are brazed onto the enclosure using gold braze 412 .
  • the feed-through wires can be adhered using a glass frit to the enclosure or otherwise molded or bonded to the enclosure.
  • the feed-through wires can be served upward and then down along the enclosure toward the stimulation lead and connected to the electrode wires 414 .
  • a platinum/iridium tube 413 is used to connect the electrode wires to the feed-through wires.
  • the proximal segment of the platinum/iridium tubing can be crimped onto the feed-through wires and the distal end of the tubing can be crimped to the electrode wires 414 .
  • the platinum/iridium tubing includes at least two witness holes 416 . These witness holes allow the operator to verify that the wires are appropriately placed prior to applying the crimp.
  • the platinum/iridium tubing can be resistance welded; laser welded, brazed, or otherwise secured using epoxy or other conductive adhesives to the feed-through and electrode wires.
  • FIG. 4 also shows the outer protective encapsulation layer (in transparency).
  • the outer protective layer is a copolymer; a blend of biocompatible urethane and silicone co-polymer uniquely compounded to provide superior adhesion to the substrate while providing a tissue friendly interface.
  • the protective layer can be molded over the stimulator body and a portion of the stimulating lead using a reaction injection molding (RIM) process.
  • the material can be stable, biocompatible, resistant to oxidation and have increased mechanical properties compared to other polyurethanes and silicones.
  • the protective layer is designed to provide electrical isolation between exposed conductors as well as a primary biocompatible interface between the tissue and the implanted device. The use of this material to surround the electrode wire interconnect assembly to the feed-through assembly provides stability and electrical insulation to each interconnection.
  • the material can also be molded onto a proximal portion of the stimulation lead to act as a strain relief.
  • FIG. 5 illustrates an alternative embodiment of an electrode wire to feed-through interconnect system similar to the embodiment described above, except that each electrode is connected to the feed-through assembly using an organic thin-film flex circuit 520 .
  • the flex circuit can comprise of a polyamide film with printed trace lines made of a conductive material such as gold.
  • the flex circuit contains at least six trace lines printed on the polyamide film with each trace line corresponding to one electrode.
  • the polyamide film is expanded near the interconnect assembly, such that the printed trace lines are equally spaced with the feed-through assembly wires. Then each trace tine on the polyamide film is extended off the film like a comb with individual fingers, each finger representing on printed trace line.
  • the polyamide film can be narrowed once it enters into the stimulating lead assembly.
  • the narrowed film is no wider than 0.5 mm, such that the film is smaller than the diameter of the lead assembly (e.g., 1.0 mm).
  • the polyamide film that comprises the flex circuit is 0 . 1 mm thick, however in other embodiments the flex circuit can be approximately 0.05 to 0.5 mm thick. In other embodiments, the flex circuit can take on the shape needed to facilitate the interconnection between the stimulation electrodes and the feed-through assembly.
  • the electronics enclosure 610 and integral feed-through wires 611 are shown and include an additional protrusion feature 612 in the feed-through assemblies.
  • the protrusion feature is used to increase the surface distance between each of the monolithic feed-through wires and provide a larger surface area for increased adhesion of the copolymer.
  • the outer protective layer is molded onto the electronics enclosure it provides stability and protects the electrical connections between the feed-through wires and the electrode wires. If fluid ingress occurs, coupled with the copolymer delaminating, the increased surface distance (i.e., the electrical path) between electrodes will help prevent electrical shorting.
  • the protrusion features extend above the surface of the electronics enclosure by approximately 0.25 mm.
  • the protrusions can extend between 0.1 to 0.5 mm above the enclosure.
  • a staggered configuration of the feed-through assemblies Due to size constraints on the electronic enclosure, the feed-through assemblies may not be able to be arranged in a linear fashion without unintended electrical shorting between two adjacent feed-through assemblies. By staggering the feed-through assemblies, an increased number of feed-through wires can be used and the distance between adjacent feed-through assemblies could be increased, reducing the risk of electrical shorting.
  • FIG. 7 is an isometric exploded view of a hermetic electronics enclosure of a neurostimulator.
  • the hermetic enclosure comprises a substrate and monolithic feed-through 721 , a bezel 723 and a lid 724 .
  • the hermetic enclosure houses the micro-electronic assembly, an inductive coil 726 and a ferrite core 727 .
  • the substrate is manufactured from stabilized zirconium oxide and the feed-through wires are gold brazed into place and are manufactured from platinum-iridium (80/20).
  • the substrate and integral monolithic feed-through assembly 721 can be manufactured from one of many ceramic materials, including, but not limited to aluminum oxide, transparent polycrystalline aluminum oxide, stabilized zirconium oxide, aluminum nitride, and silicon nitride.
  • the substrate and monolithic feed-through assembly can be produced using a variety of manufacturing methods including but not limited to post sintering machining, green form pressing and sintering, and injection molding and sintering.
  • the bezel 723 and the lid 724 can be manufactured using a high resistance, biocompatible metal such as commercially pure or alloyed titanium.
  • the bezel can be made out of but not limited to other materials including corrosion resistant stainless steels, refractory's such as aluminum oxide, transparent polycrystalline aluminum oxide, stabilized zirconium oxide, aluminum nitride, and silicon nitride or glass frit.
  • the bezel 723 is brazed at the location to the mating edge of the ceramic substrate and monolithic feed-through assembly using pure gold braze. This braze provides a gas tight seal between the bezel and the ceramic substrate of the electronics enclosure.
  • the bezel also exhibits recessed self-alignment nesting features suitable to receive and accommodate the lid 724 , which is welded to the bezel providing another gas tight seal at location between the bezel and the lid.
  • the bezel is brazed on the ceramic substrate prior to populating the electrodes within the substrate. By doing so, the titanium lid can be welded onto the titanium bezel after the electronics assembly has been populated within the substrate. The welding between the bezel and the lid can be a low temperature process, which does not affect the electronics within the enclosure.
  • the lid would need to be brazed onto the substrate, which is a high temperature process.
  • the high temperature process would adversely affect the electronics.
  • the gold braze between the substrate and the bezel can be done prior to populating the electronics within the substrate allowing a lower temperature weld to be done between the lid and the bezel after populating the electronics.
  • the electronics enclosure can house a micro-electronics assembly, an inductive coil 726 and a ferrite core 727 .
  • the inductive coil is connected and bonded into the electronics enclosure and used to inductively receive power and provide bi-directional communication with an external controller (not shown).
  • the inductive coil can be configured such that when implanted within the neurostimulator at a depth of 1-3 cm, the inductive coil can still receive power and communicate with the external controller.
  • the inductive coil can be part of an RC (resistor- capacitor) circuit designed to resonate between 120 and 130 kHz. In one embodiment, the inductive coil resonates via 2.7 to 3.3 nF capacitor.
  • the coil can be 200 turns of 41 gauge bondable solid core magnetic wire and wound into a rectangular orientation, 11.47 mm long by 5.47 mm wide, for example. In one embodiment, the thickness of the coil is 1.5 mm. In other embodiments, the coil is configured such that it includes a step on the inner surface. This step allows for the coil to sit flat on a specific surface of the ceramic substrate and clear the protrusions of the feed-through wires on another portion of the inside surface of the ceramic substrate. The step in the coil can increase the number of turns that can be allowed to fit into the electronics enclosure. The increased number of turns allows for greater distance in which the coil can be externally powered, thus allowing for a greater distance over which bi-directional communication can occur.
  • the length, width and thickness of the coil can be adjusted to fit into the electronics enclosure and configured such to optimize the power transfer and communication distances.
  • the ferrite core can be bonded into the top side of the inductive coil and used to align the magnetic flux to optimize energy transfer.
  • the micro-electronics, inductive coil and ferrite core are all contained within the electronics enclosure and hermetically sealed using a titanium lid.
  • the hermetic electronics enclosure also supports an integral fixation apparatus 728 .
  • the fixation apparatus as described above can be fixed to the enclosure, and in one embodiment the fixation apparatus is laser welded to the enclosure. In other embodiment the fixation apparatus can be bonded using standard biocompatible adhesives, or otherwise mechanical attached, e.g., swage or press fit to the hermetic enclosure.
  • the fixation apparatus includes an additional routing feature 729 located on the distal side of the stimulator body.
  • the routing feature is made from the same titanium as the fixation mini-plate and is configured to curve around the electrode wires as they pass from the stimulating lead to the stimulator body. The electrode wires are guided through the routing feature on the fixation apparatus, where they can be organized and crimped to the feed-through wires on the electronics enclosure.
  • an isometric exploded view of the hermetic electronics enclosure 810 including the integral fixation apparatus which includes the bezel 811 and a lid 812 is shown without the stimulation lead assembly and protective outer layer.
  • the fixation apparatus is integral to the bezel. The integral bezel and fixation apparatus are then brazed onto the ceramic electronics enclosure.
  • the braze bezel 811 also exhibits a recessed self-alignment nesting features suitable to receive and accommodate the lid 812 which can be welded to the braze bezel providing a gas tight seal between the braze bezel and the lid, as shown in FIG. 8 .
  • FIG. 9 illustrates one embodiment of a three-dimensional micro-electronics assembly.
  • the micro-electronics assembly comprises of an Application Specific Integrated. Circuit (ASIC) 730 , a diode array 731 , a diode array interposer 732 , an ASIC interposer, and discrete components including but not limited to a resonating capacitor 734 and a smoothing capacitor.
  • ASIC Application Specific Integrated. Circuit
  • the diode array is soldered or conductive adhesive bonded onto an organic or ceramic interposer.
  • the diode interposer provides a conductive patterned electrical circuit between the arranged diodes.
  • the diode interposer is then adhesive bonded to the upper surface of the ASIC.
  • the diode array rectifies the alternating current coming from the RC circuit which is then used to power the ASIC.
  • the AISC with the bonded diode array interposer can be adhesive bonded onto a second organic or ceramic interposer.
  • the ASIC is wire-boned using gold ball bonding or wedge bonding between exposed circuit pads on the interposer and exposed pads on the ASIC.
  • the ASIC interposer provides a patterned electrical circuit between discrete components and the ASIC including but not limited to a resonating capacitor and smoothing capacitors. The discrete components are soldered or conductive adhesive bonded to the ASIC interposer.
  • the micro-electronic assembly including the ASIC 730 , diode array 731 , diode array interposer 732 , ASIC interposer, resonating capacitor 734 and smoothing capacitor, is bonded or adhered to the lower surface of the brazed hermetic ceramic electronics enclosure, or alternatively, is printed directly into the brazed hermetic ceramic electronics enclosure.
  • the ASIC interposer contains one or more apertures 736 , which are metalized annular rings, to receive the exposed ends of the conductive feed-through pins.
  • the electrical connection between the ASIC interposer and the feed-through wire is done using conductive epoxy.
  • the electrical connections between the ASIC interposer and the feed-through wires can be done using traditional wire-bonding techniques, or soldering the metalized annular rings around the aperture to the feed-through pins.
  • the ASIC interposer described above is metalized directly onto the inner bottom surface of the ceramic substrate.
  • the metalized patterned electrical circuit is metalized using thick film, or a sputtered metal deposition to impose the circuit pattern on the substrate, in which to affix electronic components.
  • Metalizing the substrate facilitates communication between the assembled components and the outside environment at the location where the metalized substrate interfaces with the monolithic feed-through using wires brazed into the enclosure.
  • the metalized thick film or sputter is a few angstroms thick, and more specifically a 2000 angstrom thick layer of platinum and gold is laid directly on the ceramic substrate to create the patterned electrical circuit.
  • the position of the monolithic feed-through assemblies 911 on the ceramic substrate 910 can protrude through the distal wall of the ceramic substrate.
  • the substrate can be manufactured from stabilized zirconium oxide and the feed-through pins can be, gold brazed into place and can be manufactured from platinum-iridium (80/20).
  • the integral substrate and monolithic feed-through assembly may be manufactured from one of many ceramic materials, including, but not limited to aluminum oxide, transparent polycrystalline aluminum oxide, aluminum nitride, and silicon nitride.
  • the electronics enclosure, integral substrate and monolithic feed-through assembly can be produced using a variety of manufacturing methods including but not limited to post sintering machining, green form pressing and sintering, and injection molding and sintering.
  • the pins may also be manufactured from platinum or other platinum alloys, palladium, titanium, or stainless steel.
  • FIG. 12 illustrates a side view of one embodiment of the neurostimulator 1200 , which can comprise of a stimulator body 1200 a , a stimulation lead 1200 b , which contains one or more stimulation electrodes 1201 , and an integral fixation apparatus 1200 c .
  • FIG. 12 also shows two embodiments of the cross-section through the diameter of the stimulation lead 1200 b .
  • the cross-section view AA in FIG. 12 , the electrode wires or conductors 1202 that are electrically connected to the feed-through assemblies on the electronic enclosure for each electrode are discrete, independently insulated conductor wires serviced within individual lumens 1203 in the integral stimulation lead 1200 b .
  • the stimulation lead is manufactured using a multi-lumen extruded copolymer.
  • the copolymer used in the extruded multi-lumen lead is very similar to the copolymer used in the outer protective (insulating) layer that covers the stimulator body and a portion of the stimulation lead.
  • the copolymer used has an increased hardness compared to the outer protective layer copolymer.
  • the conductive electrode wires can be made of stranded platinum-iridium (90/10) wire with a diameter of 0.1 mm. In other embodiments the conductive wire can be made from but not limited to stranded or finely bundled cable assemblies or in alternate embodiments a solid wire.
  • the conductive electrode wires can be manufactured from but not limited to platinum, platinum-iridium alloy, MP35N or a variation of MP35N including a DFT, drawn and filled tubing, stainless steel, gold, or other biocompatible conductor materials.
  • the center lumen in the cross-section can includes a malleable wire segment made from platinum-iridium (90/10) with a diameter up to 0.4 mm.
  • the malleable wire segment in the center lumen in one embodiment, can be made from but not limited to platinum, platinum-iridium alloy, MP35N or a variation of MP35N including a DFT.
  • the additional of the malleable wire or other stiffening mechanism to the center lumen provides the stimulation lead assembly with added mechanical properties, such as, increasing the linear stiffness of the lead and providing increased flex fatigue properties to the entire lead assembly.
  • the increase in the linear stiffness of the stimulation lead is needed to ease the implantation of the neurostimulator.
  • the stimulation lead having a malleable wire can be configured to have the rigidity to penetrate and dissect through blunt tissue, but remain malleable enough to be bent into a shape to conform to the target anatomy.
  • the neurostimulator is configured to be implanted within the pterygopalatine fossa, a deep structure located behind the base of the nose, and just anterior the skull base.
  • the intended implantation of the neurostimulation into the pterygopalatine fossa is through a trans-oral approach using a custom implantation tool to aid in the placement of the neurostimulator.
  • An increased linear stiffness of the stimulation lead will greatly add to the ease of the implantation.
  • the intended implant location of the stimulator body is on the posterior maxilla with the stimulation lead extending to the pterygopalatine fossa along the posterior maxilla.
  • the stimulator body and the stimulator lead will be subject to compressive forces due to the motion of the surrounding anatomy from movements of the lower jaw.
  • increasing the flex fatigue resistance of the stimulation lead will increase the life time of the chronically implanted neurostimulator.
  • the center lumen of the stimulation lead may not be used to support a wire segment.
  • a supporting wire 1202 may be floating within the lumen or directly contacting the stimulation lead over-molding encapsulation, as shown in the cross-sectional view AA “ALT” on the right in FIG. 12 .
  • This view is in reference to the thin film flex circuit embodiment described above.
  • the flex circuit 1205 is suspended within the encapsulation of the stimulation lead. Also as discussed above the flex circuit contains one or more printed conductive traces 1206 that electrically connect each electrode to the feed-through assembly on the electronics enclosure.
  • FIG. 13 shows additional alternate embodiment of a neurostimulator in side view.
  • FIGS. 13 a, b, and c also show three sectional details of the neurostimulator illustrating alternative embodiments that include methods to facilitate mechanical manipulation and resistance to fatigue in-vivo.
  • FIG. 13 a shows one embodiment in which a coiled wire 1301 may be added to the proximal portion of the stimulation lead as it mates with the stimulator body.
  • the coiled wire can be manufactured from a straight or partially coiled wire made of a highly malleable biocompatible alloy such as palladium, platinum, or annealed platinum.
  • the coiled wire is configured such that the stimulation lead has optimal resistance to fatigue in vivo.
  • the following parameters can be adjusted; the diameter of the wire, the outer diameter of the coil, pitch of the coil, and the number of turns in the coil.
  • the coil was manufactured using a palladium wire with a diameter of 0.25 mm, and manufactured into a coil with 5 turns, a coil pitch of 1.0 mm, and an outer diameter 1.0 mm.
  • the coil is then suspended within the over-mold material 1302 of the lead as described above.
  • the electrode wires 1303 that electrically connect the electrodes to the feed-through interconnects transverse through the center of the coiled wire segment.
  • the supporting wire 1304 can be straight and be manufactured from more rigid materials such as titanium, stainless steel, or nitinol.
  • more rigid straight section of the wire and a coiled wire can be employed.
  • the coiled/straight material can be manufactured using the one wire or using discrete wires for each segment of the supporting wire.
  • the supporting wire can be manufactured from highly malleable biocompatible alloy such as palladium, platinum, or annealed platinum allow or from more rigid materials such as annealed titanium, stainless steel, nitinol, or any combination thereof.
  • a tapered supporting wire 1305 can be used.
  • a tapered wire with a heaver diametric cross-section proximally and tapering to a finer cross-section distally is used to provide support to the stimulation lead.
  • the tapered wire may be manufactured from either highly malleable biocompatible alloy such as palladium, platinum, or annealed platinum allow.
  • the wire can be manufactured from more rigid materials such as annealed titanium, stainless steel, or nitinol.
  • the tapered supporting wire can start at a diameter of 0.5 mm and taper to a diameter 0.1 mm at the distal portion of the wire.
  • the tapered wire can start with a diameter between 0.5 to 0.8 mm and taper to a diameter of 0.4 to 0.05 mm.
  • the tapered support wire can provide increased mechanical stability and improved flex resistance at the junction between the stimulation lead and the stimulator body, as well as provide increased bending at the distal tip of the stimulation lead over a straight non-tapered supporting wire.
  • FIGS. 14, 15 and 16 illustrate the ability of the integral stimulation lead, in one or more embodiments to be bent and/or shaped into any direction and the ability to retain the directional manipulation made to the stimulation lead during implant.
  • FIGS. 14 and 15 depict the ability of the distal stimulation lead to be bent in any direction to accommodate the needed implantation of the neurostimulator.
  • FIG. 16 depicts the ability of the entire stimulation lead to be manipulated into any angle compared to the stimulator body and retain that position during implantation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Electrotherapy Devices (AREA)

Abstract

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders. One aspect of the implantable medical device is that it includes an electronics enclosure, a substrate integral to the electronics enclosure, and a monolithic feed-through integral to the electronics enclosure and the substrate. In some embodiments, the implantable medical device can include a fixation apparatus for attaching the device to a patient.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 14/223,765, filed Mar. 24, 2014; which is a division of U.S. application Ser. No. 13/939,068, filed. Jul. 10, 2013, now U.S. Pat. No. 8,886,325; which is a continuation of U.S. application Ser. No. 12/765,712, filed Apr. 22, 2010, now U.S. Pat. No. 8,494,641; which application claims the benefit under 35 U.S.C. 119 of U.S. Provisional Application No. 61/171,749, filed Apr. 22, 2009, and U.S. Provisional Application No. 61/177,895, filed May 13, 2009. These applications are herein incorporated by reference in their entirety.
  • FIELD OF THE INVENTION
  • The invention relates generally to a stimulating apparatus used to deliver electrical stimulation to a peripheral, central or autonomic neural structure. More specifically, the current invention relates to a neurostimulator apparatus designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) to treat primary headaches, such as migraines, cluster headaches and/or many other neurological disorders, such as atypical facial pain and/or trigeminal neuralgias.
  • BACKGROUND OF THE INVENTION
  • Electrical stimulation of peripheral, central and autonomic neural structures have shown increased interest due to the potential benefits it may provide to individuals suffering from many neurological and behavioral diseases. Many of these therapies today are not well accepted or are considered last in the therapeutic options due to the invasive nature of the therapy even though the efficacy may be quite good. This has created a need for less invasive therapies that are directed toward patient and physician clinical needs.
  • Primary headaches are one of the most debilitating ailments that afflict millions of individuals worldwide. The specific pathophysiology of headaches is unknown. Known sources of headache pain consist of trauma, vascular, autoimmune, degenerative, infectious, drug and medication-induced, inflammatory, neoplastic, metabolic-endocrine, iatrogenic, musculoskeletal and myofacial causes. Also, even though the possible underlying cause of the headache pain is identified and treated, the headache pain may persist.
  • Currently, the sphenopalatine (pterygopalatine) ganglion (SPG) is a target of manipulation in clinical medicine to treat headaches. The SPG is a large extra cranial parasympathetic ganglion. It consists of parasympathetic neurons that innervate (in part) the middle cerebral and anterior cerebral blood vessels, the facial blood vessels, and the lacrimal glands. A ganglion is a mass of nervous tissue found in some peripheral and autonomic nerves. Ganglia are located on the roots of the spinal nerves and on the roots of the trigeminal nerve. Ganglia are also located on the facial, glossopharyngeal, vagus and vestibulochoclear nerves. The SPG is a complex neural ganglion with multiple connections, including autonomic, sensory and motor. The maxillary branch of the trigeminal nerve and the nerve of the pterygoid canal, also known as the vidian nerve, which is formed by the greater and deep petrosal nerves send neural projections to the SPG. The fine branches from the maxillary nerve (pterygopalatine nerves) form the sensory component of the SPG, and these fibers pass through the SPG and do not synapse. The greater petrosal nerve carries the preganglionic parasympathetic axons from the superior salivary nucleus, which is located in the Pons, to the SPG. These fibers synapse onto the postganglionic neurons within the SPG. The deep petrosal nerve connects the superior cervical sympathetic ganglion to the SPG and carries postganglionic sympathetic axons that again pass through the SPG without any synapses.
  • The sphenopalatine ganglion (SPG), also called the pterygopalatine ganglion, is located within the pterygopalatine fossa. The pterygopalatine fossa (PPF) is bounded anteriorly by the maxilla, posteriorly by the medial plate of the pterygoid process and greater wing of the sphenoid process, medially by the palatine bone, and superiorly by the body of the sphenoid process. Its lateral border is the pterygomaxillary fissure (PMF), which opens to the infratemporal fossa.
  • Treatment of the SPG is mostly performed in attempted treatments of severe headaches, such as cluster headaches or chronic migraines. Various clinical approaches have been used for over 100 years to modulate the function of the SPG to treat headaches. These procedures vary from least invasive (e.g., transnasal anesthetic blocks) to much more invasive (e.g., surgical ganglionectomy) as well as procedures such as surgical anesthetic injections, ablations, gamma knife and cryogenic surgery. Most of these procedures have very good short term efficacy outcomes (days to months), however these results are usually temporary and the headache pain returns. A chronically implanted neurostimulator apparatus designed to deliver electrical stimulation to the SPG may provide much better long term efficacy in these patients. This application details the design of a neurostimulator for this purpose.
  • SUMMARY OF THE INVENTION
  • In some embodiments, an implantable medical device configured for delivery of electrical stimulation to the Sphenopalatine Ganglion (SPG) is provided, comprising an electronics enclosure, a substrate integral to the electronics enclosure, and a monolithic feed-through integral to the electronics enclosure and the substrate.
  • In some embodiments, the device further comprises a fixation apparatus integral to the electronics enclosure. The fixation apparatus can comprise at least one preformed hole configured to accept a bone screw. In some embodiments, the fixation apparatus is malleable and configured to be formed around the zygomaticomaxillary buttress.
  • In some embodiments, the electronics enclosure comprises an ASIC, an inductive coil, and a diode array.
  • In some embodiments, the implantable medical device is sized and configured for implantation into the pterygopalatine fossa. In other embodiments, the implantable medical device is sized and configured for implantation on the posterior maxilla.
  • In one embodiment, the device further comprises a stimulation lead coupled to the electronics enclosure. The stimulation lead can be constructed to an angle off an axis of the electronics enclosure. In some embodiments, the angle is approximately 0 to 60 degrees. In other embodiments, the angle is approximately 30 degrees.
  • In one embodiment, the implantable medical device is configured to lay fiat against the posterior maxilla, and the stimulation lead is angled so as to maintain contact with the posterior maxilla as it extends to the pterygopalatine fossa.
  • In another embodiment, the stimulation lead is sized and configured to pass through a lateral opening of the pterygopalatine fossa. In some embodiments, a diameter of the stimulation lead is approximately 2-12 mm.
  • In one embodiment, the device can further comprise at least one electrode disposed on the stimulation lead. The device can further comprise at least one electrode wire coupling the at least one electrode to the electronics enclosure.
  • In some embodiments, the device further comprises a platinum/iridium tubing configured to connect the at least one electrode wire to the monolithic feed-through. In some embodiments, the platinum/iridium tubing comprises at least one witness hole.
  • In another embodiment, the device comprises a thin-film flex circuit configured to connect the at least one electrode wire to the monolithic feed-through. In another embodiment, a protrusion feature is disposed on the monolithic feed-through.
  • Some embodiments of the device further comprise an inductive coil configured to receive power and communication from an external controller at a depth of approximately 1-3 cm.
  • In some embodiments, the electronics enclosure comprises an ASIC printed on the electronics enclosure. Another embodiment further comprises at least one annular ring coupled to the electronics enclosure and configured to receive exposed ends of the monolithic feed-through.
  • Another embodiment of the device further comprises a stiffening mechanism configured to increase the linear stiffness of the stimulation lead. In some embodiments, the stiffening mechanism comprises a malleable wire. In other embodiments, the stiffening mechanism comprises a coiled wire. In yet another embodiment, the stiffening mechanism comprises a tapered supporting wire.
  • An implantable stimulator configured for delivery of electrical stimulation to a nerve is provided, comprising a housing, an electronics enclosure disposed on or in the housing, and a stimulation lead coupled to the electronics enclosure, the stimulation lead including a malleable wire configured give the stimulation lead rigidity to penetrate tissue and malleability to conform to a target anatomy.
  • In some embodiments, the stimulator comprises an attachment plate coupled to the housing, the attachment plate configured to accept a bone screw for attachment to bone.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a lateral view the neurostimulator in communication with the anatomy;
  • FIG. 2 is an isometric view of the neurostimulator;
  • FIGS. 3a-3b are top and side section views of the neurostimulator;
  • FIG. 4 is a transparent view illustrating the electrode wire interconnects;
  • FIG. 5 is a transparent view illustrating an electrode flex circuit interconnect;
  • FIG. 6 is an isometric view of a feed-through interconnect embodiment;
  • FIG. 7 is an exploded view of the neurostimulator's electronics enclosure;
  • FIG. 8 is an exploded view of an electronics enclosure embodiment;
  • FIG. 9 is an isometric view of the electronics enclosure embodiment;
  • FIG. 10 is a top down view of the neurostimulator's electronics and enclosure;
  • FIG. 11 is an isometric view of a feed-through interconnect embodiment;
  • FIG. 12 illustrates embodiments of the lead cross-sections;
  • FIG. 13 illustrates axial cross-sectional insets of lead embodiments;
  • FIG. 14 is an isometric view of an embodiment of a bendable lead;
  • FIG. 15 is an isometric view of an embodiment of a bendable lead;
  • FIG. 16 is an isometric view of an embodiment of a bendable lead.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Referring to FIG. 1, a neurostirnulator 100 is shown within the intended anatomy for the treatment of primary headaches and other neurological disorders. The neurostimulator of this embodiment comprises of a stimulator body 200 a, an integral stimulation lead 200 b, and an integral fixation apparatus 200 c. The neurostimulator 100 can be implanted such that the stimulator body 200 b is positioned medial to the zygoma 205 on the posterior maxilla 206 within the buccal fat pad of the cheek, and the integral fixation apparatus 200 c is anchored to the zygomaticomaxillary buttress 203, such as by using standard craniomaxillofacial bone screws, for example. The integral stimulation lead 200 c can be placed within the pterygopalatine fossa 202, or more specifically, in very close proximity to the sphenopalatine ganglion 204.
  • FIG. 2 illustrates one embodiment of an implantable neurostirnulator 200. In this embodiment, the neurostimulator 200 comprises of a stimulator body 200 a, an integral stimulation lead 200 b, which includes one or more stimulating electrodes 201, and an integral fixation apparatus 200 c, The neurostimulator 200 of this embodiment can be an inductively powered device having the necessary micro-electronics to store programmable stimulation parameters, deliver electrical stimulation per the programmed parameters and to allow bi-directional telemetry to enable communication with an external controller. An external transmitter (not shown) provides powers to and communications with the implanted neurostimulator.
  • The neurostimulator's micro-electronics can be housed in the stimulator body 200 a, a hermetic enclosure that protects the micro-electronics from fluid ingress when implanted within the body. The stimulator body can further include an electronics enclosure, a micro-electronics assembly, a monolithic feed-through assembly, and a lead interconnect assembly, and the stimulator body can be molded with a protective outer layer. In some embodiments the dimensions of the stimulator body are 8 mm wide, 4 mm thick, and 14 mm long.
  • The neurostimulator is sized and configured to be implanted on the posterior maxilla, so the neurostimulator thickness is limited by the available free space between the posterior maxilla and the coronoid process of the mandible. The average distance between the posterior maxilla and the coronoid process, measured from 79 patients using computed tomography, was 13±3 mm with a range of 6-24 mm (unpublished work). Thus, in some embodiments the thickness of the neurostimulator can range from 1 to 10 mm. The width and length of the neurostimulator are also limited by the surrounding anatomy, but in some embodiments the width and length are such that the neurostimulator maintains physical contact with the posterior maxilla. Thus, the neurostimulation width can range from 1-20 mm, and the length can range from 1-25 mm.
  • Electrical stimulation can be carried from the micro-electronics to one or more of the stimulating electrodes 201 through the stimulation lead 200 b. The stimulation lead can be connected to the stimulator body through a series of feed-through assemblies. In the embodiment of FIG. 2, the stimulator body 200 a and a portion of the stimulating lead 200 b are shown with a biocompatible outer layer 202, created using a reaction injection molding (RIM) process, to protect the feed-through assemblies, provide strain relief to the stimulation lead and create an isodiametric neurostimulator. The neurostimulator is isodiametric because the size is maintained or decreases from the most proximal portion of the stimulator body to the most distal portion of the stimulating lead. In addition, the configuration of the outer layer does not contain any sharp corners or edges. This allows the neurostimulator to be implanted and explanted without grabbing or tearing of surrounding tissue. In some embodiments, the outer protective layer is created from biocompatible urethane and silicone co-polymer. The protective layer can be up to 1 mm thick, however in some embodiments the protective layer can be 0.1 to 2 mm thick. In other embodiments, different encapsulations methods and materials may be used, including but not limited to, potting, injection molding, casting, conformal coating, or adhering a compliant, semi-compliant, or rigid silicone rubber, epoxy, thereto-set or thermoplastic polymers or combination of any of the described methods and materials around the electronic assembly, lead interconnect, and lead assembly.
  • Also referring to FIG. 2, the integral fixation apparatus 200 c can include a. biocompatible mini-plate with one or more preformed holes extending off the body of the neurostimulator. The preformed holes can be designed to accept a standard bone screw. For example, the preformed holes can be approximately 1.9 mm in diameter and be sized to accept a standard bone screw with a diameter between 1.5-1.8 mm. The preformed holes can also be designed with a ninety-degree chamfer that allows the head of the standard bone screw to recess into the mini-plate and reside flush with the outboard face of mini-plate. In one embodiment the mini-plate is made from titanium (grade 2), which provides both good mechanical fatigue resistance and good flexibility. However, in other embodiments, the mini-plate can be made from other materials such as: commercially pure titanium such as grades 1,3, or 4 and alloys such as grade 5 or 23; stainless steels such as 304 or 316; other biocompatible metals; and biocompatible plastics such as PEEK, nylon, or polypropylene.
  • Additionally, as shown in FIG. 2 the one or more preformed holes are set in a linear configuration off the proximal end of the stimulator body to increase the flexibility of the mini-plate. In the intended target anatomy, the mini-plate can be anchored to the thick dense bone of the zygomatic process of the maxilla, generally referred to the zygomaticomaxillary buttress. When the stimulator body is positioned on the posterior maxilla, the mini-plate must be formed around the buttress without adversely moving or dislodging the stimulator body and the stimulation lead. Thus, the mini-plate must be malleable so that it can be formed around the buttress as well as resistant to flex fatigue from repeat bending. In one embodiment, in which the mini-plate is made from titanium (grade 2), the center-to-center distance between each of the preformed holes can be 6 mm, and the width of the beam between each preformed hole can be 1.3 mm. In this embodiment, the mini-plate provides the proper amount of malleability and flex resistance needed to form the mini-plate around the buttress and to allow for long term reliability for the chronic implantable neurostimulator. Also, the second moment of area across the mini-plate is designed to be constant, which facilitates uniform bending and typically creates a larger more uniform arch. The larger arch that is formed from bending of the mini-plate helps to resist stress concentrations and promotes matching of the surface of the mini-plate to the underlying anatomical bone features. In other embodiments, the center-to-center distance between each of the preformed holes can be between 3-10 mm and the width of the beam between each preformed hole can be 0.5 to 3 mm.
  • Additionally, in another embodiment, the arrangement of the preformed holes on the mini-plate can be configured into a Y configuration (a single mini-plate extending off the stimulator body with two tails extending out like a Y), a T configuration (a single mini-plate formed into a T), an L configuration (a single mini-plate formed into an L) or an X configuration (a single mini-plate formed into a X, with one leg of the X attached to the stimulator body). In any of these configurations, each of the mini-plates can contain one or more preformed holes and include the same features described above. In additional embodiments, the neurostimulator can include one or more mini-plates projecting off the stimulator body, including but not limited to a mini-plate extending off the opposing end of the stimulator body from the stimulating lead, and one or more mini-plates extending off the two other adjacent sides of the neurostimulator.
  • FIG. 2 also illustrates the stimulating lead 200 b of neurostimulator 200. In this embodiment, the stimulating lead comprises of one or more stimulation electrodes 201 and a corresponding number of connecting lead wires for each of the stimulating electrodes. Each connecting lead wire connects to a feed-through on the stimulating body. The connecting wires provide a conduit to deliver electrical stimulation pulses between the micro-electronics and the stimulating electrodes. In one embodiment, the stimulation lead projects from the distal face of the stimulator body constructed to an angle of 30 degrees off the stimulator axis. In this embodiment, the inboard planer side of the neurostimulator body is configured to lay flat against and in interment communication with the posterior maxilla, which also coincides with the stimulator surface from which the integral fixation apparatus 200 c extends. The angle of the stimulating lead projecting off the stimulator body allows the lead to maintain contact with the posterior maxilla as it courses from the stimulator body to the pterygopalatine fossa and reduces any stress on the stimulating lead by reducing the lead curvature. In some embodiments, the degree of the angle between the stimulator body and stimulating lead can range from between approximately 0 to 60 degrees. In yet other embodiments the stimulating lead may contain multiple compound angles with the neurostimulator, the angles may be on or off axis with the stimulator body.
  • In the embodiment of FIG. 2, the stimulating lead includes seven cylindrical stimulating electrodes 201 that can be configured to provide either cathodic or anodic stimulation. In this embodiment the stimulating lead comprises at least 5 stimulating cathodic electrodes, or working electrodes. The working electrodes are configured to be implanted in very close proximity to the SPG within the pterygopalatine fossa and to be used for delivering the stimulation pulses from the micro-electronics. In some embodiments, the two most proximal electrodes to the stimulator body 200 a can be electronically coupled to create a larger reference or return electrode. This reference electrode can be configured as an anode and positioned on the stimulating lead such that it is the farthest electrode from the SPG.
  • The length and spacing of the electrodes are configured to optimize stimulation of the SPG. The average height and width of the SPG has been found to be 3.28 mm, range 2-6 mm and 1.76 mm, range 1-3 mm respectively. In some embodiments, the spacing distance between any two adjacent stimulation electrodes is no greater than 1.0 mm and each electrode is 1.5 mm in length. The electrode length and the spacing assures that at least one electrode maintains communication with the SPG. In other embodiments the electrode spacing can range from 0.3-4 mm, and the length of each electrode can range from 0.4 to 4 mm. In one embodiment, the stimulating lead and hence each electrode, is 1 mm in diameter. The diameter of the stimulating lead can be designed such that the lead passes through the lateral opening the pterygopalatine fossa, called the pterygopalatine fissure, which has been reported to be between 2-12 mm wide. In other embodiment, the diameter of the lead can range from 0.5 to 3 mm. Each stimulation electrode has a thickness of 0.1 mm; a minimum thickness of 0.05 mm is needed prevent damage during manufacturing and implantation. The stimulation electrodes can be made from 90/10 platinum/iridium alloy. However, in other embodiments the stimulation electrodes can be made from other biocompatible metallic alloys, including but not limited to platinum, platinum alloys, palladium, palladium alloys, titanium, titanium alloys, various stainless steels, or any other conductive biocompatible metals and biocompatible non-metals such as but not limited to carbon.
  • FIG. 3a is an elevated view and FIG. 3b is a sectioned side view of neurostimulator 300, and illustrates the integral design of the neurostimilator. In FIG. 3a , the neurostimulator 300 includes stimulator body 300 a, integral stimulating lead 300 b, which includes one or more stimulation electrodes 301, and integral fixation apparatus 300 c. FIG. 3b shows a sectioned side view of the neurostimulator through the line A-A in FIG. 3a . In this embodiment, the sectioned side view shows the hermetic electronics enclosure within the stimulator body 300 a, integral stimulation lead 300 b, electrode wire interconnect assembly 305 and the electrode connection wires 303. Also shown in FIG. 3b is the protective (insulation) outer layer 304, which encapsulates the stimulator body and the proximal portion of the stimulation lead. The protective layer also covers the proximal portion of the stimulation lead to provide additional strain relief at the junction between the lead and the stimulator body. This layer is formed by reaction injection molding (RIM) with a biocompatible urethane and silicone co-polymer. Other encapsulations methods and materials may include potting, injection molding, casting, conformal coating, or adhering a compliant, semi-compliant, or rigid silicone rubber, epoxy, thermo set or thermoplastic polymers or combination of any of the described methods and materials around the electronic assembly, lead interconnect, and lead assembly.
  • FIG. 4 shows an enlarged detail view of the encapsulated hermetic electronics enclosure 411, feed through assembly and interconnect assembly. The feed-through wires 410 projecting from the upper surface of the hermetic electronic enclosure 411 can be bonded to the enclosure. In some embodiments, the feed-through wires are brazed onto the enclosure using gold braze 412. In other embodiments the feed-through wires can be adhered using a glass frit to the enclosure or otherwise molded or bonded to the enclosure. The feed-through wires can be served upward and then down along the enclosure toward the stimulation lead and connected to the electrode wires 414. In some embodiments, a platinum/iridium tube 413 is used to connect the electrode wires to the feed-through wires. The proximal segment of the platinum/iridium tubing can be crimped onto the feed-through wires and the distal end of the tubing can be crimped to the electrode wires 414. The platinum/iridium tubing includes at least two witness holes 416. These witness holes allow the operator to verify that the wires are appropriately placed prior to applying the crimp. In other embodiments the platinum/iridium tubing can be resistance welded; laser welded, brazed, or otherwise secured using epoxy or other conductive adhesives to the feed-through and electrode wires.
  • FIG. 4 also shows the outer protective encapsulation layer (in transparency). In one embodiment, the outer protective layer is a copolymer; a blend of biocompatible urethane and silicone co-polymer uniquely compounded to provide superior adhesion to the substrate while providing a tissue friendly interface. The protective layer can be molded over the stimulator body and a portion of the stimulating lead using a reaction injection molding (RIM) process. The material can be stable, biocompatible, resistant to oxidation and have increased mechanical properties compared to other polyurethanes and silicones. The protective layer is designed to provide electrical isolation between exposed conductors as well as a primary biocompatible interface between the tissue and the implanted device. The use of this material to surround the electrode wire interconnect assembly to the feed-through assembly provides stability and electrical insulation to each interconnection. The material can also be molded onto a proximal portion of the stimulation lead to act as a strain relief.
  • FIG. 5 illustrates an alternative embodiment of an electrode wire to feed-through interconnect system similar to the embodiment described above, except that each electrode is connected to the feed-through assembly using an organic thin-film flex circuit 520. The flex circuit can comprise of a polyamide film with printed trace lines made of a conductive material such as gold. In one embodiment, the flex circuit contains at least six trace lines printed on the polyamide film with each trace line corresponding to one electrode. In another embodiment, the polyamide film is expanded near the interconnect assembly, such that the printed trace lines are equally spaced with the feed-through assembly wires. Then each trace tine on the polyamide film is extended off the film like a comb with individual fingers, each finger representing on printed trace line. Each trace can then be crimped onto the feed-through assembly wires as described above. The polyamide film can be narrowed once it enters into the stimulating lead assembly. In one embodiment, the narrowed film is no wider than 0.5 mm, such that the film is smaller than the diameter of the lead assembly (e.g., 1.0 mm). In one embodiment, the polyamide film that comprises the flex circuit is 0.1 mm thick, however in other embodiments the flex circuit can be approximately 0.05 to 0.5 mm thick. In other embodiments, the flex circuit can take on the shape needed to facilitate the interconnection between the stimulation electrodes and the feed-through assembly.
  • In one embodiment, as shown in 6, the electronics enclosure 610 and integral feed-through wires 611 are shown and include an additional protrusion feature 612 in the feed-through assemblies. The protrusion feature is used to increase the surface distance between each of the monolithic feed-through wires and provide a larger surface area for increased adhesion of the copolymer. Once the outer protective layer is molded onto the electronics enclosure it provides stability and protects the electrical connections between the feed-through wires and the electrode wires. If fluid ingress occurs, coupled with the copolymer delaminating, the increased surface distance (i.e., the electrical path) between electrodes will help prevent electrical shorting. In one embodiment, the protrusion features extend above the surface of the electronics enclosure by approximately 0.25 mm. In other embodiments, the protrusions can extend between 0.1 to 0.5 mm above the enclosure. Also shown in FIG. 6, is a staggered configuration of the feed-through assemblies. Due to size constraints on the electronic enclosure, the feed-through assemblies may not be able to be arranged in a linear fashion without unintended electrical shorting between two adjacent feed-through assemblies. By staggering the feed-through assemblies, an increased number of feed-through wires can be used and the distance between adjacent feed-through assemblies could be increased, reducing the risk of electrical shorting.
  • FIG. 7 is an isometric exploded view of a hermetic electronics enclosure of a neurostimulator. In this embodiment, the hermetic enclosure comprises a substrate and monolithic feed-through 721, a bezel 723 and a lid 724. The hermetic enclosure houses the micro-electronic assembly, an inductive coil 726 and a ferrite core 727. In one embodiment, the substrate is manufactured from stabilized zirconium oxide and the feed-through wires are gold brazed into place and are manufactured from platinum-iridium (80/20). In other embodiments, the substrate and integral monolithic feed-through assembly 721 can be manufactured from one of many ceramic materials, including, but not limited to aluminum oxide, transparent polycrystalline aluminum oxide, stabilized zirconium oxide, aluminum nitride, and silicon nitride. The substrate and monolithic feed-through assembly can be produced using a variety of manufacturing methods including but not limited to post sintering machining, green form pressing and sintering, and injection molding and sintering.
  • In one embodiment, the bezel 723 and the lid 724 can be manufactured using a high resistance, biocompatible metal such as commercially pure or alloyed titanium. In other embodiments, the bezel can be made out of but not limited to other materials including corrosion resistant stainless steels, refractory's such as aluminum oxide, transparent polycrystalline aluminum oxide, stabilized zirconium oxide, aluminum nitride, and silicon nitride or glass frit.
  • In one embodiment, the bezel 723 is brazed at the location to the mating edge of the ceramic substrate and monolithic feed-through assembly using pure gold braze. This braze provides a gas tight seal between the bezel and the ceramic substrate of the electronics enclosure. The bezel also exhibits recessed self-alignment nesting features suitable to receive and accommodate the lid 724, which is welded to the bezel providing another gas tight seal at location between the bezel and the lid. The bezel is brazed on the ceramic substrate prior to populating the electrodes within the substrate. By doing so, the titanium lid can be welded onto the titanium bezel after the electronics assembly has been populated within the substrate. The welding between the bezel and the lid can be a low temperature process, which does not affect the electronics within the enclosure. However, if the bezel is not used, the lid would need to be brazed onto the substrate, which is a high temperature process. The high temperature process would adversely affect the electronics. The gold braze between the substrate and the bezel can be done prior to populating the electronics within the substrate allowing a lower temperature weld to be done between the lid and the bezel after populating the electronics.
  • Referring to FIG. 7, the electronics enclosure can house a micro-electronics assembly, an inductive coil 726 and a ferrite core 727. In this embodiment the inductive coil is connected and bonded into the electronics enclosure and used to inductively receive power and provide bi-directional communication with an external controller (not shown). The inductive coil can be configured such that when implanted within the neurostimulator at a depth of 1-3 cm, the inductive coil can still receive power and communicate with the external controller. The inductive coil can be part of an RC (resistor- capacitor) circuit designed to resonate between 120 and 130 kHz. In one embodiment, the inductive coil resonates via 2.7 to 3.3 nF capacitor. The coil can be 200 turns of 41 gauge bondable solid core magnetic wire and wound into a rectangular orientation, 11.47 mm long by 5.47 mm wide, for example. In one embodiment, the thickness of the coil is 1.5 mm. In other embodiments, the coil is configured such that it includes a step on the inner surface. This step allows for the coil to sit flat on a specific surface of the ceramic substrate and clear the protrusions of the feed-through wires on another portion of the inside surface of the ceramic substrate. The step in the coil can increase the number of turns that can be allowed to fit into the electronics enclosure. The increased number of turns allows for greater distance in which the coil can be externally powered, thus allowing for a greater distance over which bi-directional communication can occur. Additionally, in other embodiments, the length, width and thickness of the coil can be adjusted to fit into the electronics enclosure and configured such to optimize the power transfer and communication distances. The ferrite core can be bonded into the top side of the inductive coil and used to align the magnetic flux to optimize energy transfer. The micro-electronics, inductive coil and ferrite core are all contained within the electronics enclosure and hermetically sealed using a titanium lid.
  • The hermetic electronics enclosure also supports an integral fixation apparatus 728. The fixation apparatus as described above can be fixed to the enclosure, and in one embodiment the fixation apparatus is laser welded to the enclosure. In other embodiment the fixation apparatus can be bonded using standard biocompatible adhesives, or otherwise mechanical attached, e.g., swage or press fit to the hermetic enclosure. Additionally, the fixation apparatus includes an additional routing feature 729 located on the distal side of the stimulator body. In one embodiment, the routing feature is made from the same titanium as the fixation mini-plate and is configured to curve around the electrode wires as they pass from the stimulating lead to the stimulator body. The electrode wires are guided through the routing feature on the fixation apparatus, where they can be organized and crimped to the feed-through wires on the electronics enclosure.
  • In an alternative embodiment, as illustrated in FIG. 8, an isometric exploded view of the hermetic electronics enclosure 810 including the integral fixation apparatus which includes the bezel 811 and a lid 812 is shown without the stimulation lead assembly and protective outer layer. In this embodiment, the fixation apparatus is integral to the bezel. The integral bezel and fixation apparatus are then brazed onto the ceramic electronics enclosure.
  • In this embodiment, the braze bezel 811 also exhibits a recessed self-alignment nesting features suitable to receive and accommodate the lid 812 which can be welded to the braze bezel providing a gas tight seal between the braze bezel and the lid, as shown in FIG. 8.
  • FIG. 9 illustrates one embodiment of a three-dimensional micro-electronics assembly. In this embodiment the micro-electronics assembly comprises of an Application Specific Integrated. Circuit (ASIC) 730, a diode array 731, a diode array interposer 732, an ASIC interposer, and discrete components including but not limited to a resonating capacitor 734 and a smoothing capacitor. In one embodiment, the diode array is soldered or conductive adhesive bonded onto an organic or ceramic interposer. The diode interposer provides a conductive patterned electrical circuit between the arranged diodes. In one embodiment, the diode interposer is then adhesive bonded to the upper surface of the ASIC. The diode array rectifies the alternating current coming from the RC circuit which is then used to power the ASIC.
  • As shown in FIG. 9, the AISC with the bonded diode array interposer can be adhesive bonded onto a second organic or ceramic interposer. In one embodiment the ASIC is wire-boned using gold ball bonding or wedge bonding between exposed circuit pads on the interposer and exposed pads on the ASIC. The ASIC interposer provides a patterned electrical circuit between discrete components and the ASIC including but not limited to a resonating capacitor and smoothing capacitors. The discrete components are soldered or conductive adhesive bonded to the ASIC interposer. In one embodiment, the micro-electronic assembly, including the ASIC 730, diode array 731, diode array interposer 732, ASIC interposer, resonating capacitor 734 and smoothing capacitor, is bonded or adhered to the lower surface of the brazed hermetic ceramic electronics enclosure, or alternatively, is printed directly into the brazed hermetic ceramic electronics enclosure.
  • In one embodiment, as shown in FIG. 9, the ASIC interposer contains one or more apertures 736, which are metalized annular rings, to receive the exposed ends of the conductive feed-through pins. The electrical connection between the ASIC interposer and the feed-through wire is done using conductive epoxy. In other embodiments the electrical connections between the ASIC interposer and the feed-through wires can be done using traditional wire-bonding techniques, or soldering the metalized annular rings around the aperture to the feed-through pins.
  • In other embodiments, as illustrated in FIG. 10, the ASIC interposer described above is metalized directly onto the inner bottom surface of the ceramic substrate. The metalized patterned electrical circuit is metalized using thick film, or a sputtered metal deposition to impose the circuit pattern on the substrate, in which to affix electronic components. Metalizing the substrate facilitates communication between the assembled components and the outside environment at the location where the metalized substrate interfaces with the monolithic feed-through using wires brazed into the enclosure. In one embodiment, the metalized thick film or sputter is a few angstroms thick, and more specifically a 2000 angstrom thick layer of platinum and gold is laid directly on the ceramic substrate to create the patterned electrical circuit.
  • In other embodiments, as illustrated in FIG. 11, the position of the monolithic feed-through assemblies 911 on the ceramic substrate 910 can protrude through the distal wall of the ceramic substrate. In this embodiment, the substrate can be manufactured from stabilized zirconium oxide and the feed-through pins can be, gold brazed into place and can be manufactured from platinum-iridium (80/20). In various other embodiments the integral substrate and monolithic feed-through assembly may be manufactured from one of many ceramic materials, including, but not limited to aluminum oxide, transparent polycrystalline aluminum oxide, aluminum nitride, and silicon nitride. Also the electronics enclosure, integral substrate and monolithic feed-through assembly can be produced using a variety of manufacturing methods including but not limited to post sintering machining, green form pressing and sintering, and injection molding and sintering. The pins may also be manufactured from platinum or other platinum alloys, palladium, titanium, or stainless steel.
  • FIG. 12 illustrates a side view of one embodiment of the neurostimulator 1200, which can comprise of a stimulator body 1200 a, a stimulation lead 1200 b, which contains one or more stimulation electrodes 1201, and an integral fixation apparatus 1200 c. FIG. 12 also shows two embodiments of the cross-section through the diameter of the stimulation lead 1200 b. In one embodiment, the cross-section view AA in FIG. 12, the electrode wires or conductors 1202 that are electrically connected to the feed-through assemblies on the electronic enclosure for each electrode are discrete, independently insulated conductor wires serviced within individual lumens 1203 in the integral stimulation lead 1200 b. In one embodiment the stimulation lead is manufactured using a multi-lumen extruded copolymer. The copolymer used in the extruded multi-lumen lead is very similar to the copolymer used in the outer protective (insulating) layer that covers the stimulator body and a portion of the stimulation lead. In this embodiment, the copolymer used has an increased hardness compared to the outer protective layer copolymer. In one embodiment, the conductive electrode wires can be made of stranded platinum-iridium (90/10) wire with a diameter of 0.1 mm. In other embodiments the conductive wire can be made from but not limited to stranded or finely bundled cable assemblies or in alternate embodiments a solid wire. The conductive electrode wires can be manufactured from but not limited to platinum, platinum-iridium alloy, MP35N or a variation of MP35N including a DFT, drawn and filled tubing, stainless steel, gold, or other biocompatible conductor materials. The center lumen in the cross-section can includes a malleable wire segment made from platinum-iridium (90/10) with a diameter up to 0.4 mm. The malleable wire segment in the center lumen, in one embodiment, can be made from but not limited to platinum, platinum-iridium alloy, MP35N or a variation of MP35N including a DFT. The additional of the malleable wire or other stiffening mechanism to the center lumen, in one embodiment, provides the stimulation lead assembly with added mechanical properties, such as, increasing the linear stiffness of the lead and providing increased flex fatigue properties to the entire lead assembly. The increase in the linear stiffness of the stimulation lead is needed to ease the implantation of the neurostimulator. For example, the stimulation lead having a malleable wire can be configured to have the rigidity to penetrate and dissect through blunt tissue, but remain malleable enough to be bent into a shape to conform to the target anatomy.
  • In one embodiment, the neurostimulator is configured to be implanted within the pterygopalatine fossa, a deep structure located behind the base of the nose, and just anterior the skull base. As described in U.S. patent application Ser. No. 61/145,122 to Papay, which is incorporated herein by reference, the intended implantation of the neurostimulation into the pterygopalatine fossa is through a trans-oral approach using a custom implantation tool to aid in the placement of the neurostimulator. An increased linear stiffness of the stimulation lead will greatly add to the ease of the implantation. Additionally, as referenced the Papay application, the intended implant location of the stimulator body is on the posterior maxilla with the stimulation lead extending to the pterygopalatine fossa along the posterior maxilla. In this location, the stimulator body and the stimulator lead will be subject to compressive forces due to the motion of the surrounding anatomy from movements of the lower jaw. Thus increasing the flex fatigue resistance of the stimulation lead will increase the life time of the chronically implanted neurostimulator.
  • Referring still to FIG. 12, in other embodiments, the center lumen of the stimulation lead may not be used to support a wire segment. In one embodiment, a supporting wire 1202 may be floating within the lumen or directly contacting the stimulation lead over-molding encapsulation, as shown in the cross-sectional view AA “ALT” on the right in FIG. 12. This view is in reference to the thin film flex circuit embodiment described above. In this embodiment, the flex circuit 1205 is suspended within the encapsulation of the stimulation lead. Also as discussed above the flex circuit contains one or more printed conductive traces 1206 that electrically connect each electrode to the feed-through assembly on the electronics enclosure.
  • FIG. 13 shows additional alternate embodiment of a neurostimulator in side view. FIGS. 13 a, b, and c also show three sectional details of the neurostimulator illustrating alternative embodiments that include methods to facilitate mechanical manipulation and resistance to fatigue in-vivo. FIG. 13a shows one embodiment in which a coiled wire 1301 may be added to the proximal portion of the stimulation lead as it mates with the stimulator body. In this embodiment the coiled wire can be manufactured from a straight or partially coiled wire made of a highly malleable biocompatible alloy such as palladium, platinum, or annealed platinum. In this embodiment the coiled wire is configured such that the stimulation lead has optimal resistance to fatigue in vivo. To optimize the flex resistance of the inserted coil within the stimulation lead the following parameters can be adjusted; the diameter of the wire, the outer diameter of the coil, pitch of the coil, and the number of turns in the coil. In one embodiment, the coil was manufactured using a palladium wire with a diameter of 0.25 mm, and manufactured into a coil with 5 turns, a coil pitch of 1.0 mm, and an outer diameter 1.0 mm. The coil is then suspended within the over-mold material 1302 of the lead as described above. In this embodiment the electrode wires 1303 that electrically connect the electrodes to the feed-through interconnects transverse through the center of the coiled wire segment.
  • In alternate embodiments, as shown in FIG. 13c , the supporting wire 1304 can be straight and be manufactured from more rigid materials such as titanium, stainless steel, or nitinol. In other embodiment, a combination between the more rigid straight section of the wire and a coiled wire can be employed. In this embodiment the coiled/straight material can be manufactured using the one wire or using discrete wires for each segment of the supporting wire. In this embodiment, the supporting wire can be manufactured from highly malleable biocompatible alloy such as palladium, platinum, or annealed platinum allow or from more rigid materials such as annealed titanium, stainless steel, nitinol, or any combination thereof.
  • In yet another alternative embodiment, as shown in FIG. 13b , a tapered supporting wire 1305 can be used. In this embodiment, a tapered wire with a heaver diametric cross-section proximally and tapering to a finer cross-section distally is used to provide support to the stimulation lead. In one embodiment, the tapered wire may be manufactured from either highly malleable biocompatible alloy such as palladium, platinum, or annealed platinum allow. In alternate embodiments the wire can be manufactured from more rigid materials such as annealed titanium, stainless steel, or nitinol. In one embodiment, the tapered supporting wire can start at a diameter of 0.5 mm and taper to a diameter 0.1 mm at the distal portion of the wire. In other embodiments, the tapered wire can start with a diameter between 0.5 to 0.8 mm and taper to a diameter of 0.4 to 0.05 mm. The tapered support wire can provide increased mechanical stability and improved flex resistance at the junction between the stimulation lead and the stimulator body, as well as provide increased bending at the distal tip of the stimulation lead over a straight non-tapered supporting wire.
  • FIGS. 14, 15 and 16 illustrate the ability of the integral stimulation lead, in one or more embodiments to be bent and/or shaped into any direction and the ability to retain the directional manipulation made to the stimulation lead during implant. FIGS. 14 and 15 depict the ability of the distal stimulation lead to be bent in any direction to accommodate the needed implantation of the neurostimulator. FIG. 16 depicts the ability of the entire stimulation lead to be manipulated into any angle compared to the stimulator body and retain that position during implantation.
  • It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described. Rather, the scope of the present invention includes both combinations and sub-combinations of the various features described, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims (16)

1-20. (canceled)
21. A system for treating a medical condition in a patient, the system comprising:
an isodiametric neurostimulator sized and dimensioned for insertion into a pterygopalatine fossa (PPF) of the patient comprising:
a stimulator body comprising a hermetic electronics enclosure housing
an electrical circuit; and
a stimulation lead extending from the hermetic electronics enclosure and
comprising electrodes integral with the electrical circuit, wherein the size of the isodiametric neurostimulator is maintained or decreases from a proximal-most portion of the stimulator body to a distal-most portion of the stimulation lead; and
an external controller in electrical communication with the neurostimulator and programmed to deliver electrical current to the patient.
22. The system of claim 21, wherein the stimulator body and a portion of the stimulation lead comprises a biocompatible outer layer.
23. The system of claim 22, wherein the biocompatible outer layer is molded to the stimulatory body and the portion of the stimulation lead.
24. The system of claim 21, wherein the isodiametric neurostimulator has a diameter between about 1 millimeter (mm) to about 10 mm.
25. The system of claim 21, wherein the isodiametric neurostimulator has a length of between about 1 mm to about 25 mm.
26. A method of treating a medical disorder in a patient comprising:
receiving an isodiametric neurostimulator within a pterygopalatine fossa (PPF) of the patient, the isodiametric neurostimulator comprising:
a stimulator body comprising a hermetic electronics enclosure housing an electrical circuit; and
a stimulation lead extending from the hermetic electronics enclosure and comprising electrodes integral with the electrical circuit, wherein the size of the isodiametric neurostimulator is maintained or decreases from a proximal-most portion of the stimulator body to a distal-most portion of the stimulation lead; and
delivering an electrical signal to a neural structure of the patient to treat the medical disorder.
27. The method of claim 26, wherein the medical disorder is pain, a movement disorder, epilepsy, a cerebrovascular disease, an autoimmune disease, a sleep disorder, an autonomic disorder, an abnormal metabolic state, a disorder of the muscular system, or a neuropsychiatric disorder.
28. The method of claim 26, wherein the medical disorder is a neurological or behavior disorder.
29. The method of claim 28, wherein the neurological disorder is a primary headache, atypical facial pain, or trigeminal neuralgia.
30. The method of claim 29, wherein the primary headache is a migraine or a cluster headache.
31. The method of claim 26, wherein the neural structure is a peripheral neural structure.
32. The method of claim 26, wherein the neural structure is an autonomic neural structure.
33. The method of claim 32, wherein the autonomic structure is a sphenopalatine ganglion.
33. The method of claim 26, wherein the neural structure is a central neural structure.
34. The method of claim 26, wherein delivering an electrical signal comprises delivering an electrical signal from an external controller.
US15/423,791 2009-04-22 2017-02-03 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism Abandoned US20170143959A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/423,791 US20170143959A1 (en) 2009-04-22 2017-02-03 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17174909P 2009-04-22 2009-04-22
US17789509P 2009-05-13 2009-05-13
US12/765,712 US8494641B2 (en) 2009-04-22 2010-04-22 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US13/939,068 US8886325B2 (en) 2009-04-22 2013-07-10 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US14/223,765 US20140207220A1 (en) 2009-04-22 2014-03-24 Implantable Neurostimulator with Integral Hermetic Electronic Enclosure, Circuit Substrate, Monolithic Feed-Through, Lead Assembly and Anchoring Mechanism
US14/858,904 US20160008608A1 (en) 2009-04-22 2015-09-18 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US15/423,791 US20170143959A1 (en) 2009-04-22 2017-02-03 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/858,904 Continuation US20160008608A1 (en) 2009-04-22 2015-09-18 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism

Publications (1)

Publication Number Publication Date
US20170143959A1 true US20170143959A1 (en) 2017-05-25

Family

ID=42992798

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/765,712 Active 2031-07-28 US8494641B2 (en) 2009-01-15 2010-04-22 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US13/939,068 Active US8886325B2 (en) 2009-04-22 2013-07-10 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US14/223,765 Abandoned US20140207220A1 (en) 2009-04-22 2014-03-24 Implantable Neurostimulator with Integral Hermetic Electronic Enclosure, Circuit Substrate, Monolithic Feed-Through, Lead Assembly and Anchoring Mechanism
US14/858,904 Abandoned US20160008608A1 (en) 2009-04-22 2015-09-18 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US15/423,791 Abandoned US20170143959A1 (en) 2009-04-22 2017-02-03 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US12/765,712 Active 2031-07-28 US8494641B2 (en) 2009-01-15 2010-04-22 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US13/939,068 Active US8886325B2 (en) 2009-04-22 2013-07-10 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US14/223,765 Abandoned US20140207220A1 (en) 2009-04-22 2014-03-24 Implantable Neurostimulator with Integral Hermetic Electronic Enclosure, Circuit Substrate, Monolithic Feed-Through, Lead Assembly and Anchoring Mechanism
US14/858,904 Abandoned US20160008608A1 (en) 2009-04-22 2015-09-18 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism

Country Status (1)

Country Link
US (5) US8494641B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097342A1 (en) * 2019-11-13 2021-05-20 Stimwave Technologies Incorporated Manufacturing implantable tissue stimulators
US20210187291A1 (en) * 2019-12-23 2021-06-24 Medtronic, Inc. Ceramic-to-metal joint for implantable pulse generators
US11439832B2 (en) 2019-01-09 2022-09-13 Stimwave Technologies Incorporated Implantable electronic devices

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US20130116745A1 (en) * 2009-01-15 2013-05-09 Autonomic Technologies, Inc. Neurostimulator system, apparatus, and method
US20130110195A1 (en) 2009-01-15 2013-05-02 Autonomic Technologies, Inc. Neurostimulator system, apparatus, and method
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US8494641B2 (en) * 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
KR101749607B1 (en) 2009-10-05 2017-06-21 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Systems, devices and methods for the treatment of neuropsychiatric disorders
US9409013B2 (en) 2009-10-20 2016-08-09 Nyxoah SA Method for controlling energy delivery as a function of degree of coupling
US9950166B2 (en) 2009-10-20 2018-04-24 Nyxoah SA Acred implant unit for modulation of nerves
US10751537B2 (en) 2009-10-20 2020-08-25 Nyxoah SA Arced implant unit for modulation of nerves
US20110319878A1 (en) * 2010-06-24 2011-12-29 Dimauro Thomas M Red Light Implants for Treating Postpartum Depression
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
ES2739490T3 (en) * 2010-11-16 2020-01-31 Univ Leland Stanford Junior Systems for the treatment of dry eye
US9364674B2 (en) 2010-11-30 2016-06-14 Ian A. Cook Pulse generator for cranial nerve stimulation
EP2651497B1 (en) 2010-12-14 2019-02-20 The Regents of The University of California Extracranial implantable systems for the treatment of medical disorders
KR20140037803A (en) 2010-12-14 2014-03-27 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Device, system and methods for the treatment of medical disorders
EP3263175B1 (en) * 2011-04-07 2021-11-24 Oculeve, Inc. Stimulation devices
US10265514B2 (en) * 2014-02-14 2019-04-23 Medtronic, Inc. Sensing and stimulation system
WO2013152316A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Subcutaneous electrodes for cranial nerve stimulation
US11253712B2 (en) 2012-07-26 2022-02-22 Nyxoah SA Sleep disordered breathing treatment apparatus
WO2014016684A2 (en) 2012-07-26 2014-01-30 Adi Mashiach Flexible antenna on flexible substrate with adhesive back
US10052097B2 (en) 2012-07-26 2018-08-21 Nyxoah SA Implant unit delivery tool
US9907967B2 (en) 2012-07-26 2018-03-06 Adi Mashiach Transcutaneous power conveyance device
US20140048977A1 (en) * 2012-08-17 2014-02-20 Autonomic Technologies, Inc. Molding of a neurostimulator for delivery into the pterygopalatine fossa
EP2722071A1 (en) * 2012-10-16 2014-04-23 Sapiens Steering Brain Stimulation B.V. A probe, especially a probe for neural applications
US9351436B2 (en) * 2013-03-08 2016-05-24 Cochlear Limited Stud bump bonding in implantable medical devices
WO2014138709A1 (en) 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
EP2967817B1 (en) 2013-03-12 2021-03-10 Oculeve, Inc. Implant delivery devices and systems
US8996137B2 (en) 2013-04-19 2015-03-31 Oculeve, Inc. Nasal stimulation devices and methods
US9308381B2 (en) 2013-06-17 2016-04-12 Nyxoah SA Ceramic encapsulation of an implantable device
US9757572B2 (en) 2013-06-28 2017-09-12 Autonomic Technologies, Inc. Implantable medical device and method for laser processing
US9427566B2 (en) 2013-08-14 2016-08-30 Syntilla Medical LLC Implantable neurostimulation lead for head pain
US9042991B2 (en) 2013-08-14 2015-05-26 Syntilla Medical LLC Implantable head mounted neurostimulation system for head pain
US9839777B2 (en) 2013-08-14 2017-12-12 Syntilla Medical LLC Implantable neurostimulation lead for head pain
US9498635B2 (en) 2013-10-16 2016-11-22 Syntilla Medical LLC Implantable head located radiofrequency coupled neurostimulation system for head pain
US10258805B2 (en) 2013-10-23 2019-04-16 Syntilla Medical, Llc Surgical method for implantable head mounted neurostimulation system for head pain
US10960215B2 (en) 2013-10-23 2021-03-30 Nuxcel, Inc. Low profile head-located neurostimulator and method of fabrication
RU2698711C2 (en) 2014-02-25 2019-08-29 Окулив, Инк. Polymers compositions for lacrimonasal stimulation
AU358535S (en) 2014-04-18 2014-11-03 Oculeve Nasal stimulator device
CA2956176A1 (en) 2014-07-25 2016-01-28 Oculeve, Inc. Stimulation patterns for treating dry eye
US9692748B2 (en) 2014-09-24 2017-06-27 Oracle International Corporation Unified provisioning of applications on devices in an enterprise system
EP3209372B1 (en) 2014-10-22 2020-07-15 Oculeve, Inc. Stimulation devices for treating dry eye
EP3209371A4 (en) 2014-10-22 2018-10-24 Oculeve, Inc. Implantable nasal stimulator systems and methods
CA2965514A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
US10524681B2 (en) 2014-11-25 2020-01-07 Medtronic Bakken Research Center B.V. Lead and a system for medical applications
US9656057B2 (en) 2014-11-25 2017-05-23 Medtronic Bakken Research Center B.V. Lead and a system for medical applications
EP3242718B1 (en) * 2015-01-09 2019-05-08 Axonics Modulation Technologies, Inc. Improved antenna and methods of use for an implantable nerve stimulator
KR101656723B1 (en) * 2015-06-30 2016-09-12 재단법인 오송첨단의료산업진흥재단 Feedthrough making method
US10688299B2 (en) 2015-09-18 2020-06-23 Bioventures, Llc Electrode for peripheral nerve stimulation
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
WO2017100530A1 (en) 2015-12-09 2017-06-15 Autonomic Technologies, Inc. Surgical tools and methods for delivering a neurostimulator into the pterygopalatine fossa
WO2017120357A1 (en) * 2016-01-06 2017-07-13 Syntilla Medical LLC Implantable head located radiofrequency coupled neurostimulation system for head pain
US9717917B2 (en) 2016-01-06 2017-08-01 Syntilla Medical LLC Charging system incorporating independent charging and communication with multiple implanted devices
US10603500B2 (en) 2016-01-29 2020-03-31 Axonics Modulation Technologies, Inc. Methods and systems for frequency adjustment to optimize charging of implantable neurostimulator
WO2017139784A1 (en) 2016-02-12 2017-08-17 Axonics Modulation Technologies, Inc. External pulse generator device and associated methods for trial nerve stimulation
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
US11478652B2 (en) * 2016-03-17 2022-10-25 Pacesetter Inc. Implantable medical device with modular injection molded header assembly and related methods of manufacture
WO2017192572A1 (en) 2016-05-02 2017-11-09 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
WO2017213978A1 (en) * 2016-06-06 2017-12-14 Mayo Foundation For Medical Education And Research Devices and methods for treating tinnitus using electrical stimulation
EP3474945B1 (en) 2016-06-27 2022-12-28 Cardiac Pacemakers, Inc. Cardiac therapy system using subcutaneously sensed p-waves for resynchronization pacing management
WO2018009392A1 (en) 2016-07-07 2018-01-11 Cardiac Pacemakers, Inc. Leadless pacemaker using pressure measurements for pacing capture verification
WO2018039322A1 (en) 2016-08-24 2018-03-01 Cardiac Pacemakers, Inc. Cardiac resynchronization using fusion promotion for timing management
CN109640809B (en) 2016-08-24 2021-08-17 心脏起搏器股份公司 Integrated multi-device cardiac resynchronization therapy using P-wave to pacing timing
JP7038115B2 (en) 2016-10-27 2022-03-17 カーディアック ペースメイカーズ, インコーポレイテッド Implantable medical device with pressure sensor
WO2018081275A1 (en) 2016-10-27 2018-05-03 Cardiac Pacemakers, Inc. Multi-device cardiac resynchronization therapy with timing enhancements
CN109982746B (en) 2016-11-21 2023-04-04 心脏起搏器股份公司 Leadless cardiac pacemaker providing cardiac resynchronization therapy
CN110022755A (en) 2016-12-02 2019-07-16 奥库利维公司 Device and method for xerophthalmia prediction and treatment recommendations
US11207532B2 (en) 2017-01-04 2021-12-28 Cardiac Pacemakers, Inc. Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system
EP3573709A1 (en) 2017-01-26 2019-12-04 Cardiac Pacemakers, Inc. Leadless device with overmolded components
US20190015662A1 (en) * 2017-07-12 2019-01-17 Milind Chandrakant Raje Monolithic component for an implantable medical device
EP3668592B1 (en) 2017-08-18 2021-11-17 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
US11679263B2 (en) * 2017-12-28 2023-06-20 Realeve, Llc Systems and methods for improving headache pain
US11110289B2 (en) 2018-03-15 2021-09-07 Palo Alto Research Center Incorporated Micro coils suitable for magnetic neural stimulation
NL2020696B1 (en) * 2018-03-30 2019-10-07 Nightbalance B V Mandibular advancement device with spaced apart sets of electrical components
US10576291B2 (en) 2018-07-31 2020-03-03 Manicka Institute Llc Subcutaneous device
US11717674B2 (en) 2018-07-31 2023-08-08 Manicka Institute Llc Subcutaneous device for use with remote device
US10716511B2 (en) 2018-07-31 2020-07-21 Manicka Institute Llc Subcutaneous device for monitoring and/or providing therapies
US11433233B2 (en) 2020-11-25 2022-09-06 Calyan Technologies, Inc. Electrode contact for a subcutaneous device
US11660444B2 (en) * 2018-07-31 2023-05-30 Manicka Institute Llc Resilient body component contact for a subcutaneous device
US10471251B1 (en) 2018-07-31 2019-11-12 Manicka Institute Llc Subcutaneous device for monitoring and/or providing therapies
WO2020185902A1 (en) 2019-03-11 2020-09-17 Axonics Modulation Technologies, Inc. Charging device with off-center coil
WO2021096816A1 (en) * 2019-11-11 2021-05-20 Manicka Institute Llc Subcutaneous device for monitoring and/or providing therapies
JP2022554398A (en) * 2019-11-11 2022-12-28 カルヤン テクノロジーズ, インコーポレーテッド Subcutaneous device for monitoring and/or therapy
US11672994B2 (en) * 2020-04-24 2023-06-13 Medtronic, Inc. Electrical stimulation device with minimally invasive delivery
CN113013334A (en) * 2021-02-05 2021-06-22 中山大学 Photoelectric conversion device and preparation method, device and system thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4715380A (en) * 1986-04-03 1987-12-29 Telectronics N.V. Capped pacer neck containing a connector assembly
US5257622A (en) * 1991-09-19 1993-11-02 Medtronic, Inc. Locking connector for implantable device
US20090276005A1 (en) * 2008-05-01 2009-11-05 Benjamin David Pless Method and Device for the Treatment of Headache
US20100185258A1 (en) * 2009-01-16 2010-07-22 The Cleveland Clinic Foundation Surgical Guide and Method for Guiding a Therapy Delivery Device into the Pterygopalatine Fossa
US8204595B2 (en) * 2002-01-29 2012-06-19 Boston Scientific Neuromodulation Corporation Lead assembly for implantable microstimulator
US20120290057A1 (en) * 2009-01-16 2012-11-15 Carl Lance Boling Apparatus and method for delivering a neurostimulator into the pterygopalatine fossa

Family Cites Families (320)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2123980A (en) 1934-07-21 1938-07-19 G M Basford Company Therapeutic treatment
US2182071A (en) 1937-08-12 1939-12-05 Johnson Lab Inc Adjustable coupling system
US3134474A (en) * 1961-09-28 1964-05-26 Moore Business Forms Inc Zig-zag typewriter form stands
US3357434A (en) 1964-04-06 1967-12-12 Avco Corp Inductively linked receiver
US3746004A (en) 1971-06-14 1973-07-17 B Jankelson Disposable electrodes for electrical stimulation of muscles and nerves of the head
US3862321A (en) 1971-07-19 1975-01-21 Astra Pharma Prod Acyl xylidide local anaesthetics
US3925469A (en) 1972-02-28 1975-12-09 Astra Pharma Prod Tetiary-alkylamino-lower-acyl-xylidide local anaesthetics
US3859103A (en) 1973-03-08 1975-01-07 Nippon Selfoc Co Ltd Optical glass body having a refractive index gradient
US3914283A (en) 1973-12-10 1975-10-21 Hoffmann La Roche Polymeric local anesthetic and anti-arrhythmic agents
US3923060A (en) 1974-04-23 1975-12-02 Jr Everett H Ellinwood Apparatus and method for implanted self-powered medication dispensing having timing and evaluator means
US3920888A (en) * 1974-06-04 1975-11-18 Nuclear Battery Corp Electrical feed-through assembly suitable for electronic devices implantable in a human body
US4217349A (en) 1974-07-01 1980-08-12 Sumitomo Chemical Company, Limited Benzisoxazole derivatives
SE399419B (en) 1974-12-20 1978-02-13 Astra Laekemedel Ab ANALOGICAL PROCEDURE FOR PRODUCTION OF NEW LOCAL ANESTHETIC ASSOCIATIONS
US4147804A (en) 1975-03-31 1979-04-03 William H. Rorer, Inc. Amidinourea local anesthetics
CH602581A5 (en) 1976-07-19 1978-07-31 Cermol Sa
US4102344A (en) 1976-11-15 1978-07-25 Mentor Corporation Stimulator apparatus for internal body organ
SE7713618L (en) 1977-12-01 1979-06-02 Astra Laekemedel Ab LOCAL ANESTHETIC MIXTURE
US4379161A (en) 1979-06-07 1983-04-05 Michel Thominet Novel substituted heterocyclic phenoxyamines, the method of preparation thereof and the use thereof as local anaesthetics
US4305402A (en) 1979-06-29 1981-12-15 Katims Jefferson J Method for transcutaneous electrical stimulation
US4298603A (en) 1979-12-06 1981-11-03 Industrial Technology Research Institute O-Aminoalkylsalicylates
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4565200A (en) 1980-09-24 1986-01-21 Cosman Eric R Universal lesion and recording electrode system
US4352820A (en) 1980-12-11 1982-10-05 Virginia Mason Research Center Method for providing long-lasting local anesthesia and compounds and compositions therefore
BE889540A (en) 1981-07-08 1982-01-08 Herstal Sa STEREOTAXIC DEVICE FOR ELECTROCOAGULATION OF GASSER GANGLIONS
US4441210A (en) 1981-09-18 1984-04-03 Hochmair Erwin S Transcutaneous signal transmission system and methods
US4397845A (en) 1982-05-19 1983-08-09 The Upjohn Company Lincomycin 3-(5'-adenylate) as anesthetic
IT1152487B (en) 1982-08-06 1986-12-31 Baldacci Lab Spa 2- (OMEGA-ALCHILAMINOALCHIL) -E 2- (OMEGA-DIALKILAMINOALCHIL) -3 - - (4 -X-BENZYLIDENE) FTALIMIDINE, PROCEDURE FOR THEIR PREPARATION AND USE
US4495174A (en) 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
US4519400A (en) 1983-04-01 1985-05-28 Biosonics, Inc. Method for stimulating salivation
US4871475A (en) 1985-10-07 1989-10-03 The Boeing Company Polysulfone and polyethersulfone oligomers
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
EP0151110B1 (en) 1983-08-01 1989-03-01 Astra Läkemedel Aktiebolag L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same
IT1164387B (en) 1983-08-05 1987-04-08 Zambon Spa N-SUBSTITUTED DERIVATIVES OF 1- (4'-ALCHILSULFONILFENIL) -2-AMINO-1,3-PROPANDIOL
US4784142A (en) 1984-01-09 1988-11-15 Pain Suppression Labs, Inc. Methodology for electronic dental analgesia
US4550733A (en) 1984-01-09 1985-11-05 Pain Suppression Labs, Inc. Electronic dental analgesia apparatus and methodology
US4856526A (en) 1984-01-09 1989-08-15 Pain Suppression Labs, Inc. Apparatus and methodology for treatment of headache syndromes
US4627438A (en) 1984-01-09 1986-12-09 Pain Suppression Labs, Inc. Electronic migraine modulator apparatus and methodology
US4646744A (en) 1984-06-29 1987-03-03 Zion Foundation Method and treatment with transcranially applied electrical signals
US4695576A (en) 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide
US4598466A (en) * 1984-11-16 1986-07-08 Cordis Corporation Feedthrough
US4592359A (en) 1985-04-02 1986-06-03 The Board Of Trustees Of The Leland Stanford Junior University Multi-channel implantable neural stimulator
AT385894B (en) 1985-10-04 1988-05-25 Basem Dr Nashef TUBULAR PROBE
SE451840B (en) 1986-01-03 1987-11-02 Astra Laekemedel Ab OPTICALLY PURE MONOHYDRATED OF S - (-) - 1-PROPYL-2 ', 6'-PIPECOLOXYLIDE HYDROCHLORIDE, SET TO PREPARE THIS AND PHARMACEUTICAL PREPARATIONS FOR LOCAL ANCHORING
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US4727145A (en) 1986-09-22 1988-02-23 Ortho Pharmaceutical Corporation 2- Or 3- aryl substituted imidazo [1,2-a]pyridines
US4718423A (en) 1986-10-17 1988-01-12 Spectramed, Inc. Multiple-function cardiovascular catheter system with very high lumenal efficiency and no crossovers
SE8605515D0 (en) 1986-12-22 1986-12-22 Astra Laekemedel Ab A LIQUID DOSAGE FORM FOR ORAL ADMINISTRATION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE
US5387587A (en) 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US4830008A (en) 1987-04-24 1989-05-16 Meer Jeffrey A Method and system for treatment of sleep apnea
US4886493A (en) 1987-10-22 1989-12-12 Jordan Yee Medical applicator process
US5038781A (en) 1988-01-21 1991-08-13 Hassan Hamedi Multi-electrode neurological stimulation apparatus
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
US4920979A (en) 1988-10-12 1990-05-01 Huntington Medical Research Institute Bidirectional helical electrode for nerve stimulation
US5458631A (en) 1989-01-06 1995-10-17 Xavier; Ravi Implantable catheter with electrical pulse nerve stimulators and drug delivery system
US4976711A (en) 1989-04-13 1990-12-11 Everest Medical Corporation Ablation catheter with selectively deployable electrodes
JP2794196B2 (en) 1989-06-20 1998-09-03 チェスト株式会社 Apnea prevention stimulator
US5227165A (en) 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
SE8904298D0 (en) 1989-12-21 1989-12-21 Astra Ab NEW COMPOUNDS
US5420151A (en) 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
EP0532546B1 (en) 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5314458A (en) 1990-06-01 1994-05-24 University Of Michigan Single channel microstimulator
WO1992007605A1 (en) 1990-11-05 1992-05-14 Ravi Xavier Implantable drug dispensing multielectrode catheter
US5676955A (en) 1990-11-09 1997-10-14 Henkel Kommanditgesellschaft Auf Aktien Local anesthetic
US5199428A (en) 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5215086A (en) 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5335657A (en) 1991-05-03 1994-08-09 Cyberonics, Inc. Therapeutic treatment of sleep disorder by nerve stimulation
US5259387A (en) 1991-09-09 1993-11-09 Quinton Instrument Company ECG muscle artifact filter system
DE59209635D1 (en) 1991-09-12 1999-04-01 Biotronik Mess & Therapieg Cardiac therapy system
US5255691A (en) 1991-11-13 1993-10-26 Medtronic, Inc. Percutaneous epidural lead introducing system and method
CA2083686C (en) 1991-11-27 2001-08-21 Ross G. Stone Tension headache reliever
US5193539A (en) 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
IT1259358B (en) 1992-03-26 1996-03-12 Sorin Biomedica Spa IMPLANTABLE DEVICE FOR DETECTION AND CONTROL OF THE SYMPATHIC-VAGAL TONE
US5330515A (en) 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5514131A (en) 1992-08-12 1996-05-07 Stuart D. Edwards Method for the ablation treatment of the uvula
SE9203733D0 (en) 1992-12-11 1992-12-11 Siemens Elema Ab defibrillation
US5344438A (en) 1993-04-16 1994-09-06 Medtronic, Inc. Cuff electrode
DK80593D0 (en) 1993-07-06 1993-07-06 Scanvaegt As PROCEDURES AND PLACES FOR WEIGHTING OBJECTIVES
US5490520A (en) 1993-09-27 1996-02-13 Schaefer Partnership Dental applicance for treating bruxism
SE9303281D0 (en) 1993-10-07 1993-10-07 Astra Ab New formulation
US5433739A (en) 1993-11-02 1995-07-18 Sluijter; Menno E. Method and apparatus for heating an intervertebral disc for relief of back pain
US5458626A (en) 1993-12-27 1995-10-17 Krause; Horst E. Method of electrical nerve stimulation for acceleration of tissue healing
SE9400447D0 (en) 1994-02-11 1994-02-11 Astra Ab New compounds
US5571159A (en) 1994-04-04 1996-11-05 Alt; Eckhard Temporary atrial defibrillation catheter and method
SE9401174D0 (en) 1994-04-07 1994-04-07 Astra Ab New combination
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5843021A (en) 1994-05-09 1998-12-01 Somnus Medical Technologies, Inc. Cell necrosis apparatus
EP0688579B1 (en) 1994-06-24 2001-08-22 St. Jude Medical AB Device for heart therapy
EP0688578B1 (en) 1994-06-24 1999-11-10 Pacesetter AB Arrhythmia detector
US5558622A (en) 1994-09-02 1996-09-24 Greenberg Surgical Technologies, Llc Mandibular border retractor and method for fixating a fractured mandible
US5540734A (en) 1994-09-28 1996-07-30 Zabara; Jacob Cranial nerve stimulation treatments using neurocybernetic prosthesis
US5560351A (en) 1994-10-07 1996-10-01 University Of Florida Transtracheal energy application and sensing system for intubation: method and apparatus
AUPM982694A0 (en) 1994-12-02 1995-01-05 University Of Queensland, The Iontophoresis method and apparatus
US5545219A (en) 1995-03-30 1996-08-13 Cochlear, Ltd. Cochlear electrode implant assemblies with positioning system therefor
US5591216A (en) 1995-05-19 1997-01-07 Medtronic, Inc. Method for treatment of sleep apnea by electrical stimulation
US5735817A (en) 1995-05-19 1998-04-07 Shantha; T. R. Apparatus for transsphenoidal stimulation of the pituitary gland and adjoining brain structures
US5640764A (en) * 1995-05-22 1997-06-24 Alfred E. Mann Foundation For Scientific Research Method of forming a tubular feed-through hermetic seal for an implantable medical device
RU2108817C1 (en) 1995-05-22 1998-04-20 Карашуров Сергей Егорович Method for treating the cases of bronchial asthma
US5540730A (en) 1995-06-06 1996-07-30 Cyberonics, Inc. Treatment of motility disorders by nerve stimulation
WO1997002000A1 (en) 1995-07-06 1997-01-23 Lee John Milligan Septum nerve stimulator
US5707400A (en) 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
AU7328796A (en) 1995-10-11 1997-05-15 Regeneration Technology Bio-active frequency generator and method
US5700282A (en) 1995-10-13 1997-12-23 Zabara; Jacob Heart rhythm stabilization using a neurocybernetic prosthesis
AR004691A1 (en) 1995-10-27 1999-03-10 Astrazeneca Ab NEW DERIVATIVES OF [3-ALCOXI-PENOXI -) - ETIL] -DIALKYLAMINE, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, THEIR USE AS LOCAL ANESTHETICS AND A PROCEDURE FOR THEIR PREPARATION
US6073048A (en) 1995-11-17 2000-06-06 Medtronic, Inc. Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
SE9504662D0 (en) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US5713922A (en) 1996-04-25 1998-02-03 Medtronic, Inc. Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain
SE9601421D0 (en) 1996-04-12 1996-04-12 Astra Ab New composition
US6094598A (en) 1996-04-25 2000-07-25 Medtronics, Inc. Method of treating movement disorders by brain stimulation and drug infusion
US5711316A (en) 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US6006134A (en) 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US6132384A (en) 1996-06-26 2000-10-17 Medtronic, Inc. Sensor, method of sensor implant and system for treatment of respiratory disorders
US6246912B1 (en) 1996-06-27 2001-06-12 Sherwood Services Ag Modulated high frequency tissue modification
US5983141A (en) 1996-06-27 1999-11-09 Radionics, Inc. Method and apparatus for altering neural tissue function
US6026326A (en) 1997-01-13 2000-02-15 Medtronic, Inc. Apparatus and method for treating chronic constipation
US6093145A (en) 1997-02-10 2000-07-25 Aesculap Ag & Co. Kg Brain spatula
US5865843A (en) 1997-04-23 1999-02-02 Medtronic Inc. Medical neurological lead with integral fixation mechanism
US5861014A (en) 1997-04-30 1999-01-19 Medtronic, Inc. Method and apparatus for sensing a stimulating gastrointestinal tract on-demand
USRE40279E1 (en) 1997-06-26 2008-04-29 Sherwood Services Ag Method and system for neural tissue modification
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20050281751A1 (en) 1997-07-21 2005-12-22 Bruce Levin Directed intranasal administration of pharmaceutical agents
US6458157B1 (en) 1997-08-04 2002-10-01 Suaning Gregg Joergen Retinal stimulator
US5824027A (en) 1997-08-14 1998-10-20 Simon Fraser University Nerve cuff having one or more isolated chambers
US6141590A (en) 1997-09-25 2000-10-31 Medtronic, Inc. System and method for respiration-modulated pacing
US5938688A (en) 1997-10-22 1999-08-17 Cornell Research Foundation, Inc. Deep brain stimulation method
US6016449A (en) 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6647296B2 (en) 1997-10-27 2003-11-11 Neuropace, Inc. Implantable apparatus for treating neurological disorders
US6146380A (en) 1998-01-09 2000-11-14 Radionics, Inc. Bent tip electrical surgical probe
US6594765B2 (en) 1998-09-29 2003-07-15 Softvault Systems, Inc. Method and system for embedded, automated, component-level control of computer systems and other complex systems
US6251126B1 (en) 1998-04-23 2001-06-26 Medtronic Inc Method and apparatus for synchronized treatment of obstructive sleep apnea
US6058331A (en) 1998-04-27 2000-05-02 Medtronic, Inc. Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control
WO1999065561A1 (en) 1998-06-19 1999-12-23 Cordis Webster, Inc. Method and apparatus for transvascular treatment of tachycardia and fibrillation
CA2275370A1 (en) 1998-06-24 1999-12-24 Owens-Illinois Closure Inc. Liquid containment and dispensing device
US7599736B2 (en) 2001-07-23 2009-10-06 Dilorenzo Biomedical, Llc Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
US7209787B2 (en) 1998-08-05 2007-04-24 Bioneuronics Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7277758B2 (en) 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US6366813B1 (en) 1998-08-05 2002-04-02 Dilorenzo Daniel J. Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease
US6104957A (en) 1998-08-21 2000-08-15 Alo; Kenneth M. Epidural nerve root stimulation with lead placement method
US6668191B1 (en) 1998-10-26 2003-12-23 Birinder R. Boveja Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator
US20060122660A1 (en) 1998-10-26 2006-06-08 Boveja Birinder R Method and system for modulating sacral nerves and/or its branches in a patient to provide therapy for urological disorders and/or fecal incontinence, using rectangular and/or complex electrical pulses
US6366814B1 (en) 1998-10-26 2002-04-02 Birinder R. Boveja External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders
US6356788B2 (en) 1998-10-26 2002-03-12 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US6269270B1 (en) 1998-10-26 2001-07-31 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy of Dementia and Alzheimer's disease utilizing an implantable lead and external stimulator
US7076307B2 (en) 2002-05-09 2006-07-11 Boveja Birinder R Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders
US20030212440A1 (en) 2002-05-09 2003-11-13 Boveja Birinder R. Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system
US6564102B1 (en) 1998-10-26 2003-05-13 Birinder R. Boveja Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator
US6615081B1 (en) 1998-10-26 2003-09-02 Birinder R. Boveja Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator
US6205359B1 (en) 1998-10-26 2001-03-20 Birinder Bob Boveja Apparatus and method for adjunct (add-on) therapy of partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US6161044A (en) 1998-11-23 2000-12-12 Synaptic Corporation Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation
AU2862200A (en) 1999-01-27 2000-08-18 Bruce H. Levin Compositions, kits, apparatus, and methods for inhibiting cerebral neurovasculardisorders and muscular headaches
US8019421B2 (en) 1999-03-05 2011-09-13 Metacure Limited Blood glucose level control
US6178349B1 (en) 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US20010025192A1 (en) 1999-04-29 2001-09-27 Medtronic, Inc. Single and multi-polar implantable lead for sacral nerve electrical stimulation
JP2001013640A (en) 1999-07-01 2001-01-19 Fuji Photo Film Co Ltd Film unit with lens
US6353792B1 (en) 1999-07-06 2002-03-05 Sudhir Murthy System and method for remote communication of traffic monitoring device data
US6308105B1 (en) 1999-07-15 2001-10-23 Medtronic Inc. Medical electrical stimulation system using an electrode assembly having opposing semi-circular arms
US6272377B1 (en) 1999-10-01 2001-08-07 Cardiac Pacemakers, Inc. Cardiac rhythm management system with arrhythmia prediction and prevention
DE50014442D1 (en) 1999-11-30 2007-08-09 Biotronik Gmbh & Co Kg Device for controlling heart rate and cardiac pumping force
WO2001041867A1 (en) 1999-12-07 2001-06-14 Krasnow Institute Adaptive electric field modulation of neural systems
US6356786B1 (en) 2000-01-20 2002-03-12 Electrocore Techniques, Llc Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain
US6356787B1 (en) 2000-02-24 2002-03-12 Electro Core Techniques, Llc Method of treating facial blushing by electrical stimulation of the sympathetic nerve chain
US6438423B1 (en) 2000-01-20 2002-08-20 Electrocore Technique, Llc Method of treating complex regional pain syndromes by electrical stimulation of the sympathetic nerve chain
US6885888B2 (en) 2000-01-20 2005-04-26 The Cleveland Clinic Foundation Electrical stimulation of the sympathetic nerve chain
US20060085046A1 (en) 2000-01-20 2006-04-20 Ali Rezai Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system
AU3361901A (en) 2000-02-17 2001-08-27 Neurodan A/S Methods and implantable systems for neural sensing and nerve stimulation
US7805188B2 (en) 2000-03-24 2010-09-28 Micor, Inc. Anesthesia conduction catheter for delivery of electrical stimulus
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7146209B2 (en) 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
CN1440256A (en) 2000-05-08 2003-09-03 布雷恩斯盖特有限公司 Method and apparatus for stimulating sphenopalatine ganglion to modify properties of BBB and cerebral blood flow
US6853858B2 (en) 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6511500B1 (en) 2000-06-06 2003-01-28 Marc Mounir Rahme Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects
US6526318B1 (en) 2000-06-16 2003-02-25 Mehdi M. Ansarinia Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions
US6405079B1 (en) 2000-09-22 2002-06-11 Mehdi M. Ansarinia Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions
US7158832B2 (en) 2000-09-27 2007-01-02 Cvrx, Inc. Electrode designs and methods of use for cardiovascular reflex control devices
US7616997B2 (en) 2000-09-27 2009-11-10 Kieval Robert S Devices and methods for cardiovascular reflex control via coupled electrodes
US8086314B1 (en) 2000-09-27 2011-12-27 Cvrx, Inc. Devices and methods for cardiovascular reflex control
US20030004549A1 (en) 2000-10-26 2003-01-02 Medtronic, Inc. Method and apparatus to minimize the effects of a cardiac insult
US8417334B2 (en) 2000-10-26 2013-04-09 Medtronic, Inc. Method and apparatus for electrically stimulating the nervous system to improve ventricular dysfunction, heart failure, and other cardiac conditions
US6832114B1 (en) 2000-11-21 2004-12-14 Advanced Bionics Corporation Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes
US6633779B1 (en) 2000-11-27 2003-10-14 Science Medicus, Inc. Treatment of asthma and respiratory disease by means of electrical neuro-receptive waveforms
US7493172B2 (en) 2001-01-30 2009-02-17 Boston Scientific Neuromodulation Corp. Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
US6735475B1 (en) 2001-01-30 2004-05-11 Advanced Bionics Corporation Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain
US20060064140A1 (en) 2001-01-30 2006-03-23 Whitehurst Todd K Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
US6788975B1 (en) 2001-01-30 2004-09-07 Advanced Bionics Corporation Fully implantable miniature neurostimulator for stimulation as a therapy for epilepsy
US6564096B2 (en) 2001-02-28 2003-05-13 Robert A. Mest Method and system for treatment of tachycardia and fibrillation
US7167751B1 (en) 2001-03-01 2007-01-23 Advanced Bionics Corporation Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation
US7047078B2 (en) 2001-03-30 2006-05-16 Case Western Reserve University Methods for stimulating components in, on, or near the pudendal nerve or its branches to achieve selective physiologic responses
US7787958B2 (en) * 2001-04-13 2010-08-31 Greatbatch Ltd. RFID detection and identification system for implantable medical lead systems
US7369897B2 (en) 2001-04-19 2008-05-06 Neuro And Cardiac Technologies, Llc Method and system of remotely controlling electrical pulses provided to nerve tissue(s) by an implanted stimulator system for neuromodulation therapies
WO2002085448A2 (en) 2001-04-20 2002-10-31 The Board Of Regents Of The University Of Oklahoma Cardiac neuromodulation and methods of using same
JP2002330934A (en) 2001-05-08 2002-11-19 Tanita Corp Autonomic nerve activity measuring instrument
US20090118780A1 (en) 2001-07-23 2009-05-07 Dilorenzo Daniel John Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions
US6554809B2 (en) 2001-08-02 2003-04-29 Teodulo Aves Epidural catheter needle
US7077842B1 (en) 2001-08-03 2006-07-18 Cosman Jr Eric R Over-the-wire high frequency electrode
JP2005501617A (en) 2001-08-28 2005-01-20 メドトロニック・インコーポレーテッド System for treating mechanical mechanical dysfunction of the heart by electrical stimulation
US6760626B1 (en) 2001-08-29 2004-07-06 Birinder R. Boveja Apparatus and method for treatment of neurological and neuropsychiatric disorders using programmerless implantable pulse generator system
US7885709B2 (en) 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US7974693B2 (en) 2001-08-31 2011-07-05 Bio Control Medical (B.C.M.) Ltd. Techniques for applying, configuring, and coordinating nerve fiber stimulation
US7778711B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US20030065374A1 (en) 2001-10-01 2003-04-03 Medtronic, Inc. Active fixation lead with helix extension indicator
US20130178829A1 (en) 2001-10-23 2013-07-11 Autonomic Technologies, Inc. Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system
US6721603B2 (en) 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US7113033B2 (en) 2002-01-31 2006-09-26 Qualcomm Incorporated Variable impedance load for a variable gain radio frequency amplifier
US7477945B2 (en) 2002-02-01 2009-01-13 The Cleveland Clinic Foundation Delivery device for stimulating the sympathetic nerve chain
US7239912B2 (en) 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US7689276B2 (en) 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
US7551964B2 (en) 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7702386B2 (en) 2002-03-22 2010-04-20 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US7236822B2 (en) 2002-03-22 2007-06-26 Leptos Biomedical, Inc. Wireless electric modulation of sympathetic nervous system
US7123959B2 (en) 2002-03-25 2006-10-17 Cardiac Pacemakers, Inc. Method and apparatus for preventing cardiac arrhythmias with endovascular stimulation
DE10213919A1 (en) 2002-03-28 2003-10-09 Imre Jordy Medical instrument and process for its manufacture
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
WO2004043218A2 (en) 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
US20050209654A1 (en) 2002-05-09 2005-09-22 Boveja Birinder R Method and system for providing adjunct (add-on) therapy for depression, anxiety and obsessive-compulsive disorders by providing electrical pulses to vagus nerve(s)
US20060004423A1 (en) 2002-05-09 2006-01-05 Boveja Birinder R Methods and systems to provide therapy or alleviate symptoms of chronic headache, transformed migraine, and occipital neuralgia by providing rectangular and/or complex electrical pulses to occipital nerves
US7191012B2 (en) 2003-05-11 2007-03-13 Boveja Birinder R Method and system for providing pulsed electrical stimulation to a craniel nerve of a patient to provide therapy for neurological and neuropsychiatric disorders
US20070067004A1 (en) 2002-05-09 2007-03-22 Boveja Birinder R Methods and systems for modulating the vagus nerve (10th cranial nerve) to provide therapy for neurological, and neuropsychiatric disorders
US20050154426A1 (en) 2002-05-09 2005-07-14 Boveja Birinder R. Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation
US20050216070A1 (en) 2002-05-09 2005-09-29 Boveja Birinder R Method and system for providing therapy for migraine/chronic headache by providing electrical pulses to vagus nerve(s)
US8036745B2 (en) 2004-06-10 2011-10-11 Bio Control Medical (B.C.M.) Ltd. Parasympathetic pacing therapy during and following a medical procedure, clinical trauma or pathology
US7003352B1 (en) 2002-05-24 2006-02-21 Advanced Bionics Corporation Treatment of epilepsy by brain stimulation
US7292890B2 (en) 2002-06-20 2007-11-06 Advanced Bionics Corporation Vagus nerve stimulation via unidirectional propagation of action potentials
US7203548B2 (en) 2002-06-20 2007-04-10 Advanced Bionics Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials
US7860570B2 (en) 2002-06-20 2010-12-28 Boston Scientific Neuromodulation Corporation Implantable microstimulators and methods for unidirectional propagation of action potentials
US7285118B1 (en) 2002-07-18 2007-10-23 Functional Neuroscience Inc. Brain stimulation lead used for lesioning
US7027860B2 (en) 2002-08-29 2006-04-11 Department Of Veterans Affairs Microstimulator neural prosthesis
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US7294101B2 (en) 2002-12-21 2007-11-13 Neuropace, Inc. Means and methods for treating headaches
WO2004062470A2 (en) 2003-01-03 2004-07-29 Advanced Neuromodulation Systems, Inc. System and method for stimulation of a person’s brain stem
US20040172084A1 (en) 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
IL154801A0 (en) 2003-03-06 2003-10-31 Karotix Internat Ltd Multi-channel and multi-dimensional system and method
US20060074450A1 (en) 2003-05-11 2006-04-06 Boveja Birinder R System for providing electrical pulses to nerve and/or muscle using an implanted stimulator
US7620454B2 (en) 2003-05-19 2009-11-17 Medtronic, Inc. Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof
US7149574B2 (en) 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
US7340298B1 (en) 2003-09-03 2008-03-04 Coaxia, Inc. Enhancement of cerebral blood flow by electrical nerve stimulation
US7447533B1 (en) * 2003-09-25 2008-11-04 Pacesetter, Inc. Implantable electronic medical device having an encapsulated optical transducer
US20050102006A1 (en) 2003-09-25 2005-05-12 Whitehurst Todd K. Skull-mounted electrical stimulation system
US20050075702A1 (en) 2003-10-01 2005-04-07 Medtronic, Inc. Device and method for inhibiting release of pro-inflammatory mediator
US7418292B2 (en) 2003-10-01 2008-08-26 Medtronic, Inc. Device and method for attenuating an immune response
US20050153885A1 (en) 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US20050143378A1 (en) 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US20090312817A1 (en) 2003-11-26 2009-12-17 Wicab, Inc. Systems and methods for altering brain and body functions and for treating conditions and diseases of the same
US7769461B2 (en) 2003-12-19 2010-08-03 Boston Scientific Neuromodulation Corporation Skull-mounted electrical stimulation system and method for treating patients
US7901351B2 (en) 2003-12-24 2011-03-08 Medical Innovations, Llc Fiberoptic otoscope system
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
EP1706178B1 (en) 2004-01-22 2013-04-24 Rehabtronics Inc. System for routing electrical current to bodily tissues via implanted passive conductors
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
GB0409806D0 (en) 2004-04-30 2004-06-09 Univ Brunel Nerve blocking method and system
EP1750799A2 (en) 2004-05-04 2007-02-14 The Cleveland Clinic Foundation Methods of treating medical conditions by neuromodulation of the sympathetic nervous system
US7286879B2 (en) 2004-07-16 2007-10-23 Boston Scientific Scimed, Inc. Method of stimulating fastigium nucleus to treat neurological disorders
US7623924B2 (en) 2004-08-31 2009-11-24 Leptos Biomedical, Inc. Devices and methods for gynecologic hormone modulation in mammals
WO2006031899A2 (en) 2004-09-10 2006-03-23 The Cleveland Clinic Foundation Intraluminal electrode assembly
WO2006034305A2 (en) 2004-09-21 2006-03-30 University Of Florida Research Foundation, Inc. Multiple lead method for deep brain stimulation
US8083671B2 (en) 2004-09-30 2011-12-27 Boston Scientific Scimed, Inc. Fluid delivery system for use with an endoscope
US7167755B2 (en) 2004-10-05 2007-01-23 Cardiac Pacemakers, Inc. Adaptive software configuration for a medical device
US8175705B2 (en) 2004-10-12 2012-05-08 Cardiac Pacemakers, Inc. System and method for sustained baroreflex stimulation
US8691877B2 (en) 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
WO2006057734A1 (en) 2004-10-21 2006-06-01 Advanced Neuromodulation Systems, Inc. New stimulation design for neuromodulation
US20070250119A1 (en) 2005-01-11 2007-10-25 Wicab, Inc. Systems and methods for altering brain and body functions and for treating conditions and diseases of the same
US8788044B2 (en) 2005-01-21 2014-07-22 Michael Sasha John Systems and methods for tissue stimulation in medical treatment
DE102005003735B4 (en) 2005-01-26 2008-04-03 Cerbomed Gmbh Device for transcutaneous stimulation of a nerve of the human body
US8600521B2 (en) 2005-01-27 2013-12-03 Cyberonics, Inc. Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity
US7561918B2 (en) 2005-01-28 2009-07-14 Cyberonics, Inc. Autocapture in a neurostimulator
US7702385B2 (en) 2005-11-16 2010-04-20 Boston Scientific Neuromodulation Corporation Electrode contact configurations for an implantable stimulator
US7853321B2 (en) 2005-03-14 2010-12-14 Boston Scientific Neuromodulation Corporation Stimulation of a stimulation site within the neck or head
US20060206165A1 (en) 2005-03-14 2006-09-14 Jaax Kristen N Occipital nerve stimulation to treat headaches and other conditions
US7640057B2 (en) 2005-04-25 2009-12-29 Cardiac Pacemakers, Inc. Methods of providing neural markers for sensed autonomic nervous system activity
US8244360B2 (en) 2005-06-09 2012-08-14 Medtronic, Inc. Regional therapies for treatment of pain
US20070027484A1 (en) 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a pancreatic disorder
US7706874B2 (en) 2005-07-28 2010-04-27 Cyberonics, Inc. Stimulating cranial nerve to treat disorders associated with the thyroid gland
US7499752B2 (en) 2005-07-29 2009-03-03 Cyberonics, Inc. Selective nerve stimulation for the treatment of eating disorders
US20070027486A1 (en) 2005-07-29 2007-02-01 Cyberonics, Inc. Medical devices for enhancing intrinsic neural activity
US7684858B2 (en) 2005-09-21 2010-03-23 Boston Scientific Neuromodulation Corporation Methods and systems for placing an implanted stimulator for stimulating tissue
US20070100411A1 (en) 2005-10-27 2007-05-03 Medtronic, Inc. Implantable medical electrical stimulation lead fixation method and apparatus
US20070106143A1 (en) 2005-11-08 2007-05-10 Flaherty J C Electrode arrays and related methods
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
EP1948301B8 (en) 2005-11-10 2014-03-12 ElectroCore LLC Electrical stimulation treatment of bronchial constriction
US7763034B2 (en) 2006-01-24 2010-07-27 Medtronic, Inc. Transobturator lead implantation for pelvic floor stimulation
AU2006337679A1 (en) 2006-02-10 2007-08-16 Electrocore, Inc. Methods and apparatus for treating anaphylaxis using electrical modulation
BRPI0709844A2 (en) 2006-03-29 2011-07-26 Catholic Healthcare West Cranial nerve micrograde electrical stimulation for the treatment of medical conditions
US20080183237A1 (en) 2006-04-18 2008-07-31 Electrocore, Inc. Methods And Apparatus For Treating Ileus Condition Using Electrical Signals
US8892214B2 (en) 2006-04-28 2014-11-18 Medtronic, Inc. Multi-electrode peripheral nerve evaluation lead and related system and method of use
US20070255368A1 (en) 2006-04-28 2007-11-01 Bonde Eric H Implantable medical electrical stimulation lead with distal fixation and method
US20080027346A1 (en) 2006-05-22 2008-01-31 The Trustees Of The University Of Pennsylvania Method and device for the recording, localization and stimulation-based mapping of epileptic seizures and brain function utilizing the intracranial and extracranial cerebral vasculature and/or central and/or peripheral nervous system
JP5250549B2 (en) 2006-06-19 2013-07-31 ハイランド インストゥルメンツ, インコーポレイテッド Apparatus and method for stimulation of biological tissue
US7894907B2 (en) 2006-06-20 2011-02-22 Ebr Systems, Inc. Systems and methods for implantable leadless nerve stimulation
US7660632B2 (en) 2006-06-30 2010-02-09 Ric Investments, Llc Method and apparatus for hypoglossal nerve stimulation
US8209013B2 (en) 2006-09-14 2012-06-26 Cardiac Pacemakers, Inc. Therapeutic electrical stimulation that avoids undesirable activation
US8688238B2 (en) 2006-10-31 2014-04-01 Medtronic, Inc. Implantable medical elongated member including fixation elements along an interior surface
US9492657B2 (en) 2006-11-30 2016-11-15 Medtronic, Inc. Method of implanting a medical device including a fixation element
US10856904B2 (en) 2006-11-30 2020-12-08 Medtronic, Inc. Flexible introducer
US7765012B2 (en) 2006-11-30 2010-07-27 Medtronic, Inc. Implantable medical device including a conductive fixation element
US7744618B2 (en) 2006-12-07 2010-06-29 Cardiac Pacemakers, Inc. Device and method for modulating renal function
US20080183246A1 (en) 2007-01-26 2008-07-31 Cyberonics, Inc. Method, apparatus and system for guiding a procedure relating to an implantable medical device
US7917230B2 (en) 2007-01-30 2011-03-29 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
US20080262566A1 (en) 2007-04-23 2008-10-23 Boston Scientific Neuromodulation Corporation Methods and systems of treating medication overuse headache
US8954162B2 (en) 2007-04-25 2015-02-10 Medtronic, Inc. Medical device implantation
AU2008260076A1 (en) 2007-05-30 2008-12-11 The Cleveland Clinic Foundation Apparatus and method for treating headache and/or facial pain
US8027737B2 (en) 2007-08-01 2011-09-27 Intelect Medical, Inc. Lead extension with input capabilities
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US7848816B1 (en) 2007-12-27 2010-12-07 Pacesetter, Inc. Acquiring nerve activity from carotid body and/or sinus
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
WO2009129480A2 (en) 2008-04-18 2009-10-22 Medtronic, Inc. Psychiatric disorder therapy control
US8142362B2 (en) * 2008-04-24 2012-03-27 Pacesetter, Inc. Enhanced pressure sensing system and method
EP2192947A1 (en) 2008-04-30 2010-06-09 Medtronic, Inc. Techniques for placing medical leads for electrical stimulation of nerve tissue
US8151795B2 (en) 2008-06-30 2012-04-10 Linde Ag Method of demand valve oxygen therapy for rapid abort of cluster headache
US8195297B2 (en) 2008-10-13 2012-06-05 E-Pacing, Inc. Devices and methods for electrical stimulation of the diaphragm and nerves
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US20130116745A1 (en) * 2009-01-15 2013-05-09 Autonomic Technologies, Inc. Neurostimulator system, apparatus, and method
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US20130110195A1 (en) * 2009-01-15 2013-05-02 Autonomic Technologies, Inc. Neurostimulator system, apparatus, and method
US8494641B2 (en) * 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US20100185249A1 (en) 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
US8321030B2 (en) 2009-04-20 2012-11-27 Advanced Neuromodulation Systems, Inc. Esophageal activity modulated obesity therapy
WO2010141481A1 (en) 2009-06-01 2010-12-09 Autonomic Technologies, Inc. Methods and devices for adrenal stimulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4715380A (en) * 1986-04-03 1987-12-29 Telectronics N.V. Capped pacer neck containing a connector assembly
US5257622A (en) * 1991-09-19 1993-11-02 Medtronic, Inc. Locking connector for implantable device
US8204595B2 (en) * 2002-01-29 2012-06-19 Boston Scientific Neuromodulation Corporation Lead assembly for implantable microstimulator
US20090276005A1 (en) * 2008-05-01 2009-11-05 Benjamin David Pless Method and Device for the Treatment of Headache
US20100185258A1 (en) * 2009-01-16 2010-07-22 The Cleveland Clinic Foundation Surgical Guide and Method for Guiding a Therapy Delivery Device into the Pterygopalatine Fossa
US20120290057A1 (en) * 2009-01-16 2012-11-15 Carl Lance Boling Apparatus and method for delivering a neurostimulator into the pterygopalatine fossa

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439832B2 (en) 2019-01-09 2022-09-13 Stimwave Technologies Incorporated Implantable electronic devices
US12017080B2 (en) 2019-01-09 2024-06-25 Curonix Llc Implantable electronic devices
WO2021097342A1 (en) * 2019-11-13 2021-05-20 Stimwave Technologies Incorporated Manufacturing implantable tissue stimulators
US12017082B2 (en) 2019-11-13 2024-06-25 Curonix Llc Manufacturing implantable tissue stimulators
US20210187291A1 (en) * 2019-12-23 2021-06-24 Medtronic, Inc. Ceramic-to-metal joint for implantable pulse generators

Also Published As

Publication number Publication date
US20130296993A1 (en) 2013-11-07
US20100274313A1 (en) 2010-10-28
US20140207220A1 (en) 2014-07-24
US8494641B2 (en) 2013-07-23
US8886325B2 (en) 2014-11-11
US20160008608A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
US8886325B2 (en) Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US10315044B2 (en) Methods for delivery of optical signals to tissue for the treatment of a disease or condition
US7974705B2 (en) Multiplexed multi-electrode neurostimulation devices
EP1861162B1 (en) Implantable neurostimulator device
US8010189B2 (en) SPG stimulation for treating complications of subarachnoid hemorrhage
US9662494B2 (en) Probe, especially a probe for neural applications
EP1578494B1 (en) Lead connection module of a modular implantable medical device
EP1861164B1 (en) Neurostimulation site screening
US11291841B2 (en) Implantable medical device structures including recharge and/or telemetry coil
US20060287677A1 (en) SPG stimulation via the greater palatine canal
US9393432B2 (en) Non-hermetic direct current interconnect
US20140343621A1 (en) Probe system for brain applications
US8954151B2 (en) RF resistant feedthrough assembly and electrical stimulation systems containing the assembly
JP2023161029A (en) Pair of intelligent electric conductors
US9119970B2 (en) Feedthrough assembly with glass layer and electrical stimulation systems containing the assembly
US20160375237A1 (en) Systems and methods for making and using electrical stimulation leads with coated contacts
US10524681B2 (en) Lead and a system for medical applications
EP3946569B1 (en) Low-profile control module for an electrical stimulation system
US20230001183A1 (en) Medical lead reconfiguration system
CN106621028A (en) Electrode lead

Legal Events

Date Code Title Description
AS Assignment

Owner name: AUTONOMIC TECHNOLOGIES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOLING, CARL LANCE;PLESS, BENJAMIN DAVID;POWELL, RYAN;AND OTHERS;REEL/FRAME:043809/0705

Effective date: 20100528

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION